US20140187488A1 - Methods for maintaining pegylation of polypeptides - Google Patents
Methods for maintaining pegylation of polypeptides Download PDFInfo
- Publication number
- US20140187488A1 US20140187488A1 US14/117,458 US201214117458A US2014187488A1 US 20140187488 A1 US20140187488 A1 US 20140187488A1 US 201214117458 A US201214117458 A US 201214117458A US 2014187488 A1 US2014187488 A1 US 2014187488A1
- Authority
- US
- United States
- Prior art keywords
- peg
- polypeptides
- polypeptide
- seq
- pegylated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 218
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 187
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 178
- 238000000034 method Methods 0.000 title claims abstract description 61
- 230000006320 pegylation Effects 0.000 title claims abstract description 43
- 238000003860 storage Methods 0.000 claims abstract description 34
- 229920001223 polyethylene glycol Polymers 0.000 claims description 166
- 239000002202 Polyethylene glycol Substances 0.000 claims description 149
- 239000000203 mixture Substances 0.000 claims description 44
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 38
- 210000004899 c-terminal region Anatomy 0.000 claims description 31
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 25
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 9
- 102000002090 Fibronectin type III Human genes 0.000 claims description 6
- 108050009401 Fibronectin type III Proteins 0.000 claims description 6
- 230000006323 depegylation Effects 0.000 abstract description 51
- 108010067306 Fibronectins Proteins 0.000 abstract description 25
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 abstract description 20
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 abstract description 20
- 101710204410 Scaffold protein Proteins 0.000 abstract description 20
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 102000016359 Fibronectins Human genes 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 description 87
- 108090000623 proteins and genes Proteins 0.000 description 87
- 235000018102 proteins Nutrition 0.000 description 80
- 235000001014 amino acid Nutrition 0.000 description 64
- 229940024606 amino acid Drugs 0.000 description 60
- 150000001413 amino acids Chemical class 0.000 description 59
- 239000000243 solution Substances 0.000 description 26
- 230000027455 binding Effects 0.000 description 25
- 238000009739 binding Methods 0.000 description 25
- 102100037362 Fibronectin Human genes 0.000 description 24
- 238000006467 substitution reaction Methods 0.000 description 24
- 238000009472 formulation Methods 0.000 description 22
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 20
- 125000000539 amino acid group Chemical group 0.000 description 19
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 18
- 239000012634 fragment Substances 0.000 description 17
- 239000001632 sodium acetate Substances 0.000 description 17
- 235000017281 sodium acetate Nutrition 0.000 description 17
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 15
- 229930195725 Mannitol Natural products 0.000 description 15
- 239000000594 mannitol Substances 0.000 description 15
- 235000010355 mannitol Nutrition 0.000 description 15
- 230000001965 increasing effect Effects 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 230000021615 conjugation Effects 0.000 description 12
- 241000894007 species Species 0.000 description 12
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 10
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 10
- 239000011230 binding agent Substances 0.000 description 10
- 238000000105 evaporative light scattering detection Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000000600 sorbitol Substances 0.000 description 10
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 9
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 9
- 239000000427 antigen Substances 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000012217 deletion Methods 0.000 description 9
- 230000037430 deletion Effects 0.000 description 9
- 238000004007 reversed phase HPLC Methods 0.000 description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 9
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 8
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 8
- QXOHLNCNYLGICT-YFKPBYRVSA-N Met-Gly Chemical group CSCC[C@H](N)C(=O)NCC(O)=O QXOHLNCNYLGICT-YFKPBYRVSA-N 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000003446 ligand Substances 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical group SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 7
- 239000004472 Lysine Substances 0.000 description 7
- 125000003277 amino group Chemical group 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 238000003776 cleavage reaction Methods 0.000 description 7
- 239000000539 dimer Substances 0.000 description 7
- 230000008642 heat stress Effects 0.000 description 7
- 230000002209 hydrophobic effect Effects 0.000 description 7
- 108010005942 methionylglycine Proteins 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 230000007017 scission Effects 0.000 description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000005847 immunogenicity Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 238000012430 stability testing Methods 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 5
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 5
- 108091006006 PEGylated Proteins Proteins 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- -1 for example Proteins 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 239000013632 covalent dimer Substances 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000000825 ultraviolet detection Methods 0.000 description 4
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 3
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- 238000006845 Michael addition reaction Methods 0.000 description 3
- 241001662443 Phemeranthus parviflorus Species 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000006172 buffering agent Substances 0.000 description 3
- 238000009295 crossflow filtration Methods 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 238000012395 formulation development Methods 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 210000003000 inclusion body Anatomy 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000017854 proteolysis Effects 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- KZNQNBZMBZJQJO-UHFFFAOYSA-N 1-(2-azaniumylacetyl)pyrrolidine-2-carboxylate Chemical compound NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 description 2
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- PFYXSUNOLOJMDX-UHFFFAOYSA-N bis(2,5-dioxopyrrolidin-1-yl) carbonate Chemical compound O=C1CCC(=O)N1OC(=O)ON1C(=O)CCC1=O PFYXSUNOLOJMDX-UHFFFAOYSA-N 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 238000005277 cation exchange chromatography Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000000269 nucleophilic effect Effects 0.000 description 2
- AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000004845 protein aggregation Effects 0.000 description 2
- 238000006268 reductive amination reaction Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000013060 ultrafiltration and diafiltration Methods 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- FQWZLZJRZNURGX-BYPYZUCNSA-N (2s)-2-(2-diazohydrazinyl)-4-methylsulfanylbutanoic acid Chemical group CSCC[C@@H](C(O)=O)NN=[N+]=[N-] FQWZLZJRZNURGX-BYPYZUCNSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000055025 Adenosine deaminases Human genes 0.000 description 1
- 102000008102 Ankyrins Human genes 0.000 description 1
- 108010049777 Ankyrins Proteins 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 101100421450 Drosophila melanogaster Shark gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 241001501930 Gavia Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 1
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000019298 Lipocalin Human genes 0.000 description 1
- 108050006654 Lipocalin Proteins 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000000470 PDZ domains Human genes 0.000 description 1
- 108050008994 PDZ domains Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 241001415846 Procellariidae Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 108091008103 RNA aptamers Proteins 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 238000003800 Staudinger reaction Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102100026966 Thrombomodulin Human genes 0.000 description 1
- 108010079274 Thrombomodulin Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- SIIZPVYVXNXXQG-UQTMIEBXSA-N [(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-4-[[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methyl [(2r,3r,4r,5r)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl] hydrogen phos Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](COP(O)(=O)O[C@H]2[C@@H](O[C@H](COP(O)(O)=O)[C@H]2O)N2C3=NC=NC(N)=C3N=C2)[C@@H](O)[C@H]1OP(O)(=O)OC[C@H]([C@@H](O)[C@H]1O)O[C@H]1N1C(N=CN=C2N)=C2N=C1 SIIZPVYVXNXXQG-UQTMIEBXSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 239000012615 aggregate Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- HUTDDBSSHVOYJR-UHFFFAOYSA-H bis[(2-oxo-1,3,2$l^{5},4$l^{2}-dioxaphosphaplumbetan-2-yl)oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O HUTDDBSSHVOYJR-UHFFFAOYSA-H 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N butyl alcohol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 150000001923 cyclic compounds Chemical class 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- GCSAXWHQFYOIFE-UHFFFAOYSA-N dipyridin-2-yl carbonate Chemical compound C=1C=CC=NC=1OC(=O)OC1=CC=CC=N1 GCSAXWHQFYOIFE-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012537 formulation buffer Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000003574 free electron Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000005661 hydrophobic surface Effects 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229920001427 mPEG Polymers 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Chemical class 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 108010025221 plasma protein Z Proteins 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 239000013636 protein dimer Substances 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000007151 ring opening polymerisation reaction Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 238000012807 shake-flask culturing Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000008362 succinate buffer Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 238000011191 terminal modification Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6435—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
Definitions
- PEGylation is a process by which polyethylene glycol (PEG) polymer chains are covalently conjugated to other molecules such as drugs or proteins. This chemical modification confers on the conjugate molecules many of the properties of PEG polymers, including hydrophilicity, structural flexibility, high mobility in solution, and low toxicity. With these new properties, PEGylated therapeutic agents show improved efficacy as compared to their unconjugated counterparts, due to increased serum half life, water solubility, protection from proteolytic degradation, low immunogenicity, and/or stability of the PEGylated molecules.
- PEGylation is a reversible reaction and dePEGylation has been observed during formulation development, stability monitoring, and storage of some therapeutic proteins. This creates a heterogeneous mixture of PEGylated and dePEGylated molecules, which may lose efficacy, safety, and other benefits of PEGylation. Accordingly, there remains a need for maintaining PEGylation of therapeutic molecules during storage of these molecules.
- compositions comprising a polypeptide conjugated to a PEG moiety through a maleimide linker, wherein the composition has a pH between pH 2.0 and pH 6.0.
- the composition may have a pH between pH 3.0 and pH 5.0.
- the composition may have a pH between pH 3.5 and pH 4.5.
- less than 5% of the maleimide linkers are cleaved over a 4, 8, 12 or more week storage period.
- the polypeptide may comprise a domain or region that binds specifically to a target protein, such as a tenth fibronectin type III ( 10 Fn3) domain having an altered amino acid sequence relative to the wild-type sequence that binds to a target molecule with a K D of less than 500 nM.
- the 10 Fn3 domain may comprise at least one loop region that differs from a naturally occurring loop region and at least one beta strand that differs from the naturally occurring beta strand.
- the 10 Fn3 domain does not contain a DK sequence in the C-terminal tail region.
- the C-terminal tail of the 10 Fn3 domain may comprise a cysteine residue, to which the PEG moiety is linked.
- the polypeptide may further comprise a second 10 Fn3 domain having an altered amino acid sequence relative to the wild-type sequence that binds to a target molecule with a K D of less than 500 nM.
- the first and second 10 Fn3 domains may bind to different targets.
- the first and second 10 Fn3 domains may be connected by a polypeptide linker comprising from 1-30 amino acids.
- the polypeptide linker may be selected from the group consisting of: a glycine-serine linker, a glycine-proline linker, a proline-alanine linker and an Fn linker.
- the maleimide linker may form a thioether bond with a sulfhydryl group on the polypeptide.
- the 10 Fn3 domain may comprise at least two loop regions that differ from the corresponding naturally occurring loop regions.
- An exemplary composition comprises a polypeptide conjugated to a PEG moiety through a maleimide linker, wherein the composition has a pH between pH 3.0 and pH 5.0 and wherein (i) the polypeptide comprises a 10 Fn3 domain having an altered amino acid sequence relative to the wild-type sequence that binds to a target molecule with a K D of less than 500 nM; (ii) the 10 Fn3 domain comprises at least one loop region that differs from the naturally occurring corresponding loop region and at least one beta strand that differs from the naturally occurring corresponding beta strand; (iii) the 10 Fn3 domain does not contain a DK sequence in the C-terminal tail region; and the 10 Fn3 domain comprises a cysteine residue, to which the PEG mo
- polypeptides are conjugated to a polyethylene glycol (PEG) moiety through a maleimide linker.
- PEG polyethylene glycol
- the maleimide linker may connect the PEG moiety to the polypeptide via a thioether bond with a sulfhydryl group on the polypeptide.
- less than 25%, 20%, 15%, 10%, 5%, 2%, 1%, 0.5%, 0.2% or 0.1% of the maleimide linkers are cleaved over a storage period of at least four weeks, eight weeks, six months, or one year.
- the PEGylated polypeptides comprise a tenth fibronectin type III ( 10 Fn3) domain having an altered amino acid sequence relative to the wild-type sequence that binds to a target molecule with a K D of less than 500 nM.
- the 10 Fn3 domain may have a C-terminal tail that does not contain a DK sequence, which has been found to be susceptible to cleavage in certain instances at pHs below 6.0.
- the 10 Fn3 domain may contain a cysteine residue that serves as the site for attachment of the PEG moiety, preferably in the C-terminal tail region.
- the PEGylated polypeptides are a multivalent polypeptide comprising two or more 10 Fn3 domains.
- Each 10 Fn3 domain may comprise an altered amino acid sequence relative to the wild-type sequence such that it binds to a target molecule with a K D of less than 500 nM.
- the first and second 10 Fn3 domains bind to the same or different targets.
- the first and second 10 Fn3 domains may be connected by a polypeptide linker comprising from 1-30 amino acids.
- Exemplary polypeptide linkers include, for example, a glycine-serine linker, a glycine-proline linker, a proline-alanine linker or an Fn linker.
- the PEGylated polypeptides are stored in a formulation comprising (a) 25 mM succinate, 5% sorbitol; (b) 10 mM sodium acetate, 5% mannitol; or (c) 10 mM sodium acetate/2% mannitol, 100 mM sodium chloride.
- the concentration of PEGylated polypeptides in the storage solution is from 1-10 mg/mL, 1-5 mg/mL, 0.5-2 mg/mL, or 4-6 mg/mL, or is about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mg/mL.
- the methods involve storing the PEGylated polypeptides at a temperature from 4-30° C., 4-25° C., 4-15° C., 4-10° C., 10-30° C., or 10-25° C., or at 4, 10, 15, 20, 25 or 30° C.
- the application provides a method for improving the stability of PEGylated polypeptides in a solution, wherein the polypeptides are conjugated to a polyethylene glycol (PEG) moiety through a maleimide linker, comprising the steps of: (a) determining the amount of PEG cleaved from the polypeptides over a fixed storage period in the solution; and (b) if PEG is cleaved from more than 5% of the polypeptides over the storage period, reformulating the PEGylated polypeptides in a storage solution buffered to a pH of between 2.0-6.0.
- PEG polyethylene glycol
- FIG. 1 illustrates the mechanism of Michael Addition, showing the ligation between a protein (R′) via its sulfhydryl group and the PEG molecule (R).
- FIG. 2A-B shows the RP-HPLC profile of a FBSP-P stability sample (10 mg/mL, formulated in 10 mM succinate, 5% (w/v) sorbitol, 1.2% (w/v) alanine, pH 6.0; incubated at 25° C. for four weeks).
- B ELSD trace showing the detection of free intact PEG.
- FIG. 3 shows UV (280 nm) profile of a FBSP-P stability sample (1 mg/mL, formulated in 25 mM succinate, 1% glycine, pH 7.5; incubated at 25° C. for two weeks) from an LC-MS analysis.
- FIG. 4 presents a graph showing an increase in mole % of free PEG in FBSP-P samples formulated at different pH, during 25° C. stability testing for two weeks. Protein was formulated at 1 mg/mL in 25 mM succinate, 5% (w/v) sorbitol, at the pH indicated.
- FIG. 5 is a graph showing an increase in mole % of free PEG in FBSP-P samples formulated at different pH, during 37° C. stability testing for two weeks. Protein was formulated at 1 mg/mL in 25 mM succinate, 5% (w/v) sorbitol, at the pH indicated.
- FIG. 6A-B shows the increase in % free (unPEGylated) ADNECTINTM in FBSP-P samples formulated at different pH, during 25° C. stability testing for two weeks.
- Free ADNECTINTM refers to the sum of both the monomeric and dimeric form of the unPEGylated protein. Protein was formulated at 1 mg/mL in 25 mM succinate, 5% (w/v) sorbitol, at the pH indicated.
- FIG. 7 shows the increase in % free (unPEGylated) ADNECTINTM in FBSP-P samples formulated at different pH, during 37° C. stability testing for two weeks.
- Free ADNECTINTM refers to the sum of both the monomeric and dimeric form of the unPEGylated protein. Protein was formulated at 1 mg/mL in 25 mM succinate, 5% (w/v) sorbitol, at the pH indicated.
- FIG. 8A-D is a series of UV profiles (at 280 nm) of FBSP-V stressed samples at different pH values, obtained from LC-MS analysis.
- FBSP-V free refers to the free (unPEGylated) ADNECTINTM of FBSP-V. Only the pre-peak region of the UV profile is shown. All samples (10 mM sodium acetate, 5% mannitol) were stressed at 25° C. for a period of 6 months.
- FIG. 8A shows the UV profile of a sample at 5 mg/mL protein concentration, pH 4.5.
- FIG. 8B shows the UV profile of a sample at 5 mg/mL, pH 5.5.
- FIG. 8C shows the UV profile of a sample at 5 mg/mL, pH 6.5.
- FIG. 8D shows the UV profile a sample at 10 mg/mL, 10 mM NaOAc, 5% mannitol, pH 6.5.
- Lanes 1 and 5 are FBSP-V formulated in 10 mM sodium acetate, 2% mannitol, 100 mM sodium chloride, pH 4.5 at 5 mg/mL.
- Lanes 2 and 6 are each FBSP-V formulated in 10 mM sodium acetate, 5% mannitol, pH 4.5, at 5 mg/mL protein concentration.
- Lanes 3 and 7 are FBSP-V formulated in 10 mM sodium acetate, 5% mannitol, pH 5.5, at 5 mg/mL protein concentration.
- Lanes 4 and 8 are FBSP-V formulated in 10 mM sodium acetate, 5% mannitol, pH 6.5, at 5 mg/mL protein concentration. All FBSP-V lanes were loaded equally at 10 ⁇ g each. The arrow indicates the presence of a band corresponding to the free FBSP-V free ADNECTINTM.
- FIG. 10 is the UV profile (280 nm) of a stressed FBSP-V/I sample (10 mM acetate, 150 mM sodium chloride, pH 5.5, 5 mg/mL; 25 C for 4 weeks). Peak assignments shown were based on LC-MS analysis.
- FIG. 11 shows a comparison of dePEGylation in several ADNECTINSTM, as a measure of free PEG over the course of 1-4 weeks.
- the exemplary ADNECTINSTM are FBSP-P (samples F1, F2, and F3) stored at pH6.0; FBSP-V/I stored at pH 5.5 (VI); FBSP-V stored at pH 5.0 (V); and FBSP-E/I stored at pH 4.0 (EI).
- FIG. 12 shows the structure of a 2-branched PEG-MAL with a C2 alkyl linker, conjugated to a protein through cysteine residue.
- the profiles from top to bottom are those of: (1) free peptide; (2) peptide conjugated to ME-400MA (C2 linker) linear PEG; (3) peptide conjugated to GLE-400MA3 (C5 linker) 2-branched PEG; and peptide conjugated to GLE-400MA (C2 linker) 2-branched PEG.
- FIG. 14 shows HPLC profiles of a synthetic peptide conjugated to three different 40 kD PEG-MALs in a composition at pH 8.3 (same as in FIG. 13 ), after one week at 37° C.
- the profiles from top to bottom are those of: (1) free peptide; (2) peptide conjugated to ME-400MA (C2 linker) linear PEG; (3) peptide conjugated to GLE-400MA3 (C5 linker) 2-branched PEG; and peptide conjugated to GLE-400MA (C2 linker) 2-branched PEG.
- FIG. 17 is a histogram showing the increased percentage of free C7 protein derived from PEGylated C7 proteins after one week of heat stress of the PEGylated C7 proteins at 37° C. relative to T0, comparing samples formulated in pH 4.5 sodium acetate and pH 8.0 Tris.
- the methods of the present application may be used to maintain a polyethylene glycol (PEG) moiety on PEGylated conjugates, particularly protein or peptide therapeutics, during manufacture and/or storage of the PEGylated conjugates.
- PEG polyethylene glycol
- These methods have broad applicability to proteins and peptides that have been PEGylated to overcome issues with stability, degradation, clearance, and tolerance in subjects.
- the process of PEGylation links polyethylene glycol chains to candidate therapeutics to produce larger conjugates that show improved efficacy as compared to their unconjugated counterparts, due to increased serum half life, increased solubility, increased protection from proteolytic degradation, reduced immunogenicity, and/or increased stability of the PEGylated molecules.
- the present application describes methods to preserve PEGylation and all of its associated benefits and methods to inhibit dePEGylation of PEGylated conjugates.
- the application provides methods to inhibit cleavage of PEG moieties conjugated to polypeptides through a maleimide linker by formulating and storing the PEGylated polypeptides in a solution buffered to a pH value between pH 2.0 and pH 6.0.
- the methods described herein are based on the observation that certain PEGylated conjugates are subject to significant cleavage of the PEG moiety from the polypeptide resulting in regeneration of the free (unPEGylated) polypeptide and formation of protein aggregates and/or disulfide-linked polypeptide dimers.
- the present methods inhibit dePEGylation by maintaining PEGylated polypeptide conjugates at a pH below 6.0.
- the methods may apply to PEGylated polypeptides that are conjugated to PEG through a maleimide moiety.
- polypeptide By a “polypeptide” is meant any sequence of two or more amino acids, regardless of length, post-translation modification, or function. “Polypeptide”, “peptide”, and “protein” are used interchangeably herein. Polypeptides can include natural amino acids and non-natural amino acids such as those described in U.S. Pat. No. 6,559,126, incorporated herein by reference.
- Polypeptides can also be modified in any of a variety of standard chemical ways (e.g., an amino acid can be modified with a protecting group; the carboxy-terminal amino acid can be made into a terminal amide group; the amino-terminal residue can be modified with groups to, e.g., enhance lipophilicity; or the polypeptide can be chemically glycosylated or otherwise modified to increase stability or in vivo half-life).
- Polypeptide modifications can include the attachment of another structure such as a cyclic compound or other molecule to the polypeptide and can also include polypeptides that contain one or more amino acids in an altered configuration (i.e., R or S; or, L or D).
- Percent (%) amino acid sequence identity herein is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in a selected sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN, ALIGN-2 or Megalign (DNASTAR®) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full-length of the sequences being compared.
- % amino acid sequence identity values are obtained as described below by using the sequence comparison computer program ALIGN-2.
- the ALIGN-2 sequence comparison computer program was authored by Genentech, Inc. has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087, and is publicly available through Genentech, Inc., South San Francisco, Calif.
- the ALIGN-2 program should be compiled for use on a UNIX operating system, preferably digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.
- the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B is calculated as follows: 100 times the fraction X/Y where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A.
- the “half-life” of a polypeptide is the time taken for the concentration of the polypeptide to fall to half its original value.
- the “serum half-life” of a polypeptide can generally be defined as the time taken for the serum concentration of the polypeptide to be reduced by 50%, in vivo, for example due to degradation of the polypeptide and/or clearance or sequestration of the polypeptide by natural mechanisms.
- the half-life can be determined in any manner known per se, such as by pharmacokinetic analysis.
- Suitable techniques for determining half-life e.g., serum half-life, will be clear to the person skilled in the art, and may, for example, generally involve the steps of administering a suitable dose of a polypeptide to a primate; collecting blood samples or other samples from said primate at regular intervals; determining the level or concentration of the polypeptide in said blood sample; and calculating, from (a plot of) the data thus obtained, the time until the level or concentration of the polypeptide has been reduced by 50% compared to the initial level upon dosing.
- Half-life can be expressed using parameters such as the t1/2-alpha, t1/2-beta and the area under the curve (AUC).
- an “increase in half-life” refers to an increase in any one of these parameters, any two of these parameters, or in all three these parameters.
- an increase in half-life refers to an increase in the t1/2-beta, either with or without an increase in the t1/2-alpha and/or the AUC or both.
- shelf-life of a pharmaceutical product is the length of time the product is stored before decomposition occurs.
- shelf-life may be defined as the time for decomposition of 0.1%, 0.5%, 1%, 5%, or 10% of the product.
- a “purified” polypeptide or PEGylated polypeptide is preferably at least 85% pure, more preferably at least 95% pure, and most preferably at least 98% or 99% pure. Regardless of the exact numerical value of the purity, the polypeptide or PEGylated polypeptide is sufficiently pure for use as a pharmaceutical product.
- DePEGylation is defined as the loss of at least one PEG moiety from a PEGylated conjugate molecule, resulting in the regeneration of the intact free polypeptide and the intact free PEG moiety. This reaction may result in decreased bioavailability, decreased blood circulation, increased immunogenicity, and decreased efficacy of a therapeutic agent, as compared to its PEGylated form. Following dePEGylation, the free polypeptides may undesirably form dimers or aggregates.
- dePEGylation exposes free cysteine residues that could interact with one another through intermolecular disulfide linkages to form protein dimers.
- dePEGylation may result in exposure of hydrophobic surfaces that could lead to protein aggregation.
- DePEGylation may be measured using methods known in the art, such as reverse phase high performance liquid chromatography (RP-HPLC). Dual absorbance detectors may be used, for example, UV absorbance may be used for the detection of polypeptide species, while an evaporative light scattering detector (ELSD) may be used to detect the PEG moieties.
- ELSD evaporative light scattering detector
- LC-MS liquid chromatograph-mass spectrometry
- RP-HPLC may be used to characterize the integrity of the free PEG released from the conjugate using retention time of the released PEG as compared to the retention time for a PEG standard. For those PEGylated conjugates that were generated by maleimide chemistry, the free PEG produced by dePEGylation of the conjugate may contain the maleimide functional group.
- Factors which affect PEGylation include, but are not limited to, conditions of the original PEGylation reaction, length of storage of the PEGylated molecules, storage temperature, composition of the buffers and/or solutions in which the molecules are made and/or stored, pH of the storage buffers and/or solutions, and identity of the proteins that have been conjugated to PEG.
- PEGylation is maintained by storing the PEGylated polypeptides in a solution buffered to a pH value between pH 2.0 and pH 6.0.
- the PEGylated polypeptides are stored in a solution buffered to a pH value between pH 2.0-6.0, 2.0-5.0, 2.0-4.0, 2.0-3.0, 2.0-2.5, 3.0-6.0, 3.0-5.0, 3.0-4.0, 3.0-3.5, 4.0-6.0, 4.0-5.0, 4.0-4.5, 2.5-3.5, or 2.5-3.5.
- the PEGylated polypeptides are stored in a solution buffered to a pH of 4.0, 4.5, 5.0, 5.5, or 6.0.
- Suitable formulations for storing PEGylated polypeptides in accordance with the methods described herein are pharmaceutically acceptable compositions comprising a PEGylated polypeptide as described herein, wherein the composition is essentially endotoxin or pyrogen free.
- Formulations to be used for in vivo administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes.
- Therapeutic formulations comprising PEGylated polypeptides are prepared for storage by mixing the PEGylated polypeptides having the desired degree of purity with optional physiologically acceptable carriers, excipients or stabilizers (Osol, A., ed., Remington's Pharmaceutical Sciences , 16th Edition (1980)), in the form of aqueous solutions, lyophilized or other dried formulations.
- physiologically acceptable carriers excipients or stabilizers
- Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, sodium acetate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyidimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as alanine, glycine,
- Suitable solutions for storing the PEGylated polypeptides generally contain from 1-100 mM, 10-100 mM, 25-100 mM, 50-100 mM, 1-50 mM, 1-25 mM, 1-10 mM, 10-50 mM 10-25 mM, 10-20 mM, 10-15 mM of a buffering agent.
- the solutions for storing the PEGylated polypeptides contain 10 mM buffer or 25 mM of a buffering agent.
- Exemplary buffering agents include, for example, citrate, histidine, succinate or sodium acetate.
- Exemplary formulations for storing PEGylated polypeptides may be selected from (a) 25 mM succinate, 5% sorbitol; (b) 10 mM sodium acetate, 5% mannitol; and (c) 10 mM sodium acetate/2% mannitol, 100 mM sodium chloride.
- the concentration of PEGylated polypeptide in a formulation for storage ranges from 0.5-15 mg/mL, 0.5-5 mg/mL, 0.5-2 mg/mL, 1-10 mg/mL, 1-5 mg/mL, 1-2 mg/Ml, 3-10 mg/mL, 3-8 mg/mL, 3-6 mg/mL, 3-5 mg/mL, 4-10 mg/mL, 4-8 mg/mL, 4-6 mg/mL, 5-10 mg/mL, 5-8 mg/mL, or 5-6 mg/mL.
- the concentration of PEGylated polypeptide in a formulation for storage may be about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 mg/mL.
- the methods described herein may be used to maintain PEGylation and/or inhibit dePEGylation of polypeptides having one, two, three, four or more PEG moieties per polypeptide molecule.
- the methods described herein are used in connection with PEGylated polypeptides having only a single PEG per polypeptide.
- Formulations of PEGylated polypeptides may be suitable for administration via any desirable route.
- the formulations may be suitable for administration intravenously as a bolus or by continuous infusion over a period of time, by intramuscular, subcutaneous, intra-articular, intrasynovial, intrathecal, oral, topical, or inhalation routes.
- PEGylation is maintained for at least 2 weeks, 4 weeks, 3 months, 6 months, 1 year or more. PEGylation may also be maintained for over 1 year, or for as long as the activity of the PEGylated conjugate remains at therapeutically effective levels. There percentage of PEGylation maintained is determined relative to the initial level of PEGylation of the PEGylated polypeptide. For example, at least 98% of PEGylation is maintained for a two week period if less than 2% of the polypeptides have lost a PEG moiety after storage for two weeks as compared to the level of PEGylation at time zero.
- the methods described herein may involve maintaining PEGylation during storage of a PEGylated polypeptide at a fixed temperature over time or during storage at variable temperatures.
- PEGylation may be maintained during storage at 4° C., 15° C., 20° C., 25° C., 30° C., or 37° C.
- PEGylation may be maintained, for example, during storage at 4° C. for 2 weeks followed by storage at 25° C. for 1 week.
- the level of dePEGylation should be determined relative the initial level of PEGylation of the polypeptide.
- the methods described herein may involve first determining whether a PEGylated polypeptide is subject to dePEGylation at an undesirable level when stored at pH ⁇ 6.0.
- the methods may comprise determining the level of dePEGylation of a PEGylated polypeptide during storage at pH ⁇ 6.0. If the level of dePEGylation is greater than 1%, 2%, 5%, 10% or 15%, the PEGylated polypeptide is reformulated in a solution having a pH ⁇ 6.0.
- the methods may involve monitoring the PEGylation level of a PEGylated polypeptide formulated in a solution having a pH ⁇ 6.0 for a period of time.
- the polypeptide may be reformulated in a solution having a pH ⁇ 6.0.
- dePEGylation may be inhibited by a method comprising the steps of: (a) measuring PEGylation of the PEGylated polypeptides at an initial reference time point; (b) comparing PEGylation of the PEGylated polypeptides after an interval; (c) reducing pH of the solution to a value between pH 2.0 and pH 6.0; and (d) comparing PEGylation of the PEGylated polypeptides after an interval, wherein a decrease in dePEGylation of the PEGylated polypeptides after step (c) indicates inhibition of dePEGylation.
- a method for inhibiting dePEGylation when storing PEGylated polypeptides may comprise: (a) storing the PEGylated polypeptides in a solution; (b) monitoring the PEGylation of the PEGylated polypeptides; and (c) lowering the pH of the solution to a value in between pH 2.0 and pH 6.0, wherein the pH is a value sufficient to inhibit dePEGylation.
- the methods and formulations described herein may be applied to any PEGylated polypeptide.
- the methods described herein are particularly suited to maintaining PEGylation of polypeptides that are susceptible to dePEGylation when stored in solutions having a pH ⁇ 6.0.
- the PEGylated polypeptides are therapeutic proteins, such as, for example, interferon alpha, adenosine deaminase, L-asparaginase, granulocyte colony-stimulating factor and antibodies, such as, for example, anti-tumor necrosis factor alpha antibodies.
- a PEGylated protein may be a protein binding specifically to a target, such as an antibody or an antigen binding fragment thereof and may be any of the following: a Fab, a F(ab′)2, an Fv, a single chain Fv fragment, a single domain antibody or a variant thereof (e.g., a heavy or light chain variable domain monomer or dimer, e.g., V H , V HH ); a single chain Fc fragment, a diabody (dAb), a camelid antibody; one, two, or all three complementarity determining regions (CDRs) grafted onto a repertoire of VH or VL domains, or other scaffolds, an Affibody molecule (e.g., an Affibody protein Z scaffold or other molecules as described, e.g., in Lee et al., Clin.
- a target such as an antibody or an antigen binding fragment thereof and may be any of the following: a Fab, a F(ab′)2,
- lipocalin ankyrin repeats
- LDL receptor domain RNA aptamer
- PDZ domain a multispecific (e.g., bivalent or bispecific) antibody or fragment thereof, a human antibody or antigen binding fragment thereof, a humanized antibody or antigen binding fragment thereof, a chimeric antibody or antigen binding fragment thereof, a camelid antibody or antigen binding fragment thereof, a shark antibody or antigen binding fragment thereof, or an in vitro generated antibody or antigen binding fragment thereof.
- the PEGylated polypeptide is a fibronectin based scaffold protein (FBSP) as described further below.
- FBSP fibronectin based scaffold protein
- Exemplary FBSP include, for example, monovalent FBSP that bind to, for example, PCSK9 (FBSP-P) or VEGFR2 (FBSP-V), or multivalent FBSP, including, for example, bivalent FBSP that bind to VEGFR2 and IGF-1R (FBSP-VI).
- the methods disclosed herein may be used to maintain PEGylation of fibronectin based scaffold proteins.
- This family of proteins is capable of evolving to bind any compound of interest.
- These proteins generally make use of a scaffold derived from a fibronectin type III (Fn3) or Fn3-like domain and function in a manner characteristic of natural or engineered antibodies (that is, polyclonal, monoclonal, or single-chain antibodies) and, in addition, possess structural advantages. Specifically, the structure of these antibody mimics has been designed for optimal folding, stability, and solubility, even under conditions that normally lead to the loss of structure and function in antibodies.
- An example of fibronectin-based scaffold proteins are ADNECTINSTM (Adnexus, a wholly owned subsidiary of Bristol-Myers Squibb). Fibronectin-based scaffold proteins and ADNECTINSTM may be monovalent or multivalent.
- Fn3 domain is small, monomeric, soluble, and stable. It lacks disulfide bonds and, therefore, is stable under reducing conditions.
- the overall structure of Fn3 resembles the immunoglobulin fold.
- Fn3 domains comprise, in order from N-terminus to C-terminus, a beta or beta-like strand, A; a loop, AB; a beta or beta-like strand, B; a loop, BC; a beta or beta-like strand, C; a loop, CD; a beta or beta-like strand, D; a loop, DE; a beta or beta-like strand, E; a loop, EF; a beta or beta-like strand, F; a loop, FG; and a beta or beta-like strand, G.
- the seven antiparallel ⁇ -strands are arranged as two beta sheets that form a stable core, while creating two “faces” composed of the loops that connect the beta or beta-like strands.
- Loops AB, CD, and EF are located at one face and loops BC, DE, and FG are located on the opposing face. Any or all of loops AB, BC, CD, DE, EF and FG may participate in ligand binding.
- There are at least 15 different modules of Fn3 and while the sequence homology between the modules is low, they all share a high similarity in tertiary structure.
- amino acid sequence of the naturally occurring human tenth fibronectin type III domain i.e., the tenth module of human Fn3 ( 10 Fn3), is set forth in SEQ ID NO: 1:
- the AB loop corresponds to residues 15-16
- the BC loop corresponds to residues 21-30
- the CD loop corresponds to residues 39-45
- the DE loop corresponds to residues 51-56
- the EF loop corresponds to residues 60-66
- the FG loop corresponds to residues 76-87.
- beta strand A corresponds to residues 9-14
- beta strand B corresponds to residues 17-20
- beta strand C corresponds to residues 31-38
- beta strand D corresponds to residues 46-50
- beta strand E corresponds to residues 57-59
- beta strand F corresponds to residues 67-75
- beta strand G corresponds to residues 88-94.
- the strands are connected to each other through the corresponding loop, e.g., strands A and B are connected via loop AB in the formation strand A, loop AB, strand B, etc.
- the first 8 amino acids of SEQ ID NO:1 may be deleted while still retaining binding activity of the molecule.
- Residues involved in forming the hydrophobic core include the amino acids corresponding to the following amino acids of SEQ ID NO: 1: L8, V10, A13, L18, 120, W22, Y32, 134, Y36, F48, V50, A57, 159, L62, Y68, 170, V72, A74, 188, 190 and Y92, wherein the core amino acid residues are represented by the single letter amino acid code followed by the position at which they are located within SEQ ID NO: 1. See e.g., Dickinson et al., J. Mol. Biol., 236:1079-1092 (1994).
- 10 Fn3 are structurally analogous to antibodies, specifically the variable region of an antibody. While 10 Fn3 domains may be described as “antibody mimics” or “antibody-like proteins”, they do offer a number of advantages over conventional antibodies. In particular, they exhibit better folding and thermostability properties as compared to antibodies, and they lack disulphide bonds, which are known to impede or prevent proper folding under certain conditions.
- the BC, DE, and FG loops of 10 Fn3 are analogous to the complementary determining regions (CDRs) from immunoglobulins. Alteration of the amino acid sequence in these loop regions changes the binding specificity of 10 Fn3. 10 Fn3 domains with modifications in the AB, CD and EF loops may also be made in order to produce a molecule that binds to a desired target.
- the protein sequences outside of the loops are analogous to the framework regions from immunoglobulins and play a role in the structural conformation of the 10 Fn3. Alterations in the framework-like regions of 10 Fn3 are permissible to the extent that the structural conformation is not so altered as to disrupt ligand binding.
- amino acid residues corresponding to residues 21-30, 51-56, and 76-87 of SEQ ID NO: 1 define the BC, DE and FG loops, respectively.
- the BC loop may be defined by amino acids corresponding to residues 23-30 of SEQ ID NO: 1
- the DE loop may be defined by amino acids corresponding to residues 52-55 of SEQ ID NO: 1.
- insertions and deletions in the loop regions may also be made while still producing high affinity 10 Fn3 binders.
- one or more loops selected from BC, DE, and FG may be extended or shortened in length relative to the corresponding loop in wild-type human 10 Fn3.
- the length of the loop may be extended by from 2-25 amino acids.
- the length of the loop may be decreased by 1-11 amino acids.
- the FG loop of 10 Fn3 is 12 residues long, whereas the corresponding loop in antibody heavy chains ranges from 4-28 residues. To optimize antigen binding, therefore, the length of the FG loop of 10 Fn3 may be altered in length as well as in sequence to cover the CDR3 range of 4-28 residues to obtain the greatest possible flexibility and affinity in antigen binding.
- the integrin-binding motif “arginine-glycine-aspartic acid” (RGD), located at residues 79-81 of SEQ ID NO: 1, may be modified in order to disrupt integrin binding.
- RGD sequence may be replaced with SGE.
- the non-ligand binding sequences of 10 Fn3, i.e., the “ 10 Fn3 scaffold”, may be altered provided that the 10 Fn3 retains ligand binding function and/or structural stability.
- one or more of Asp 7, Glu 9, and Asp 23 are replaced by another amino acid, such as, for example, a non-negatively charged amino acid residue (e.g., Asn, Lys, etc.).
- a non-negatively charged amino acid residue e.g., Asn, Lys, etc.
- These mutations have been reported to have the effect of promoting greater stability of the mutant 10 Fn3 at neutral pH as compared to the wild-type form (See, PCT Publication No. WO 02/04523).
- a variety of additional alterations in the 10 Fn3 scaffold that are either beneficial or neutral have been disclosed. See, for example, Batori et al., Protein Eng., 15(12):1015-1020 (2002); Koide et al., Biochemistry, 40(34):10326
- Residues involved in forming the hydrophobic core include the amino acids corresponding to the following amino acids of SEQ ID NO: 1: L8, V10, A13, L18, 120, W22, Y32, 134, Y36, F48, V50, A57, 159, L62, Y68, 170, V72, A74, 188, 190 and Y92, wherein the core amino acid residues are represented by the single letter amino acid code followed by the position at which they are located within SEQ ID NO: 1. See e.g., Dickinson et al., J. Mol. Biol., 236:1079-1092 (1994).
- the hydrophobic core amino acids are not modified relative to the wild-type sequence.
- the following hydrophobic amino acids may be mutated: W22 and/or L62.
- the 10 Fn3 scaffold may be modified by one or more conservative substitutions. As many as 5%, 10%, 20% or even 30% or more of the amino acids in the 10 Fn3 scaffold may be altered by a conservative substitution without substantially altering the affinity of the 10 Fn3 for a ligand.
- the scaffold may comprise anywhere from 0-15, 0-10, 0-8, 0-6, 0-5, 0-4, 0-3, 1-15, 1-10, 1-8, 1-6, 1-5, 1-4, 1-3, 2-15, 2-10, 2-8, 2-6, 2-5, 2-4, 5-15, or 5-10 conservative amino acid substitutions.
- the substitutions in the scaffold do not include substitutions of the hydrophobic core amino acid residues.
- the scaffold modification reduces the binding affinity of the 10 Fn3 binder for a ligand by less than 100-fold, 50-fold, 25-fold, 10-fold, 5-fold, or 2-fold. It may be that such changes will alter the immunogenicity of the 10 Fn3 in vivo, and where the immunogenicity is decreased, such changes will be desirable.
- conservative substitutions refers to replacement of one amino acid with another amino acid that is physically or functionally similar to the amino acid being replaced. That is, a conservative substitution and its reference residue have similar size, shape, electric charge, chemical properties including the ability to form covalent or hydrogen bonds, or the like.
- conservative substitutions are those fulfilling the criteria defined for an accepted point mutation in Dayhoff et al., Atlas of Protein Sequence and Structure, 5:345-352 (1978 & Supp.).
- Examples of conservative substitutions are substitutions within the following groups: (a) valine, glycine; (b) glycine, alanine; (c) valine, isoleucine, leucine; (d) aspartic acid, glutamic acid; (e) asparagine, glutamine; (f) serine, threonine; (g) lysine, arginine, methionine; and (h) phenylalanine, tyrosine.
- a fibronectin based scaffold protein comprises a 10 Fn3 domain having at least 40%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, or 90% identity to the human 10 Fn3 domain having the amino acid sequence of SEQ ID NO: 1. Much of the variability will generally occur in one or more of the loops.
- Each of the beta or beta-like strands of a 10 Fn3 domain in a fibronectin based scaffold protein may comprise, consist essentially of, or consist of an amino acid sequence that is at least 80%, 85%, 90%, 95% or 100% identical to the sequence of a corresponding beta or beta-like strand of SEQ ID NO: 1, provided that such variation does not disrupt the stability of the polypeptide in physiological conditions.
- the 10 Fn3 domain binds to a desired target with a K D of less than 500 nM, 100 nM, 10 nM, 1 nM, 500 pM, 100 pM or less.
- the fibronectin based scaffold protein binds specifically to a target that is not bound by a wild-type 10 Fn3 domain, particularly the wild-type human 10 Fn3 domain.
- the fibronectin based scaffold protein comprises a 10 Fn3 domain having an amino acid sequence at least 80, 85, 90, 95, 98, or 100% identical to the non-loop regions of SEQ ID NO: 1, wherein at least one loop selected from BC, DE, and FG is altered.
- the altered BC loop has up to 10 amino acid substitutions, up to 4 amino acid deletions, up to 10 amino acid insertions, or a combination thereof.
- the altered DE loop has up to 6 amino acid substitutions, up to 4 amino acid deletions, up to 13 amino acid insertions, or a combination thereof.
- the FG loop has up to 12 amino acid substitutions, up to 11 amino acid deletions, up to 25 amino acid insertions, or a combination thereof.
- the disclosure provides polypeptides comprising a 10 Fn3 domain, wherein the 10 Fn3 domain comprises a loop, AB; a loop, BC; a loop, CD; a loop, DE; a loop, EF; and a loop, FG; and has at least one loop selected from loop BC, DE, and FG with an altered amino acid sequence relative to the sequence of the corresponding loop of the human 10 Fn3 domain.
- the BC and FG loops are altered.
- the BC, DE, and FG loops are altered, i.e., the 10 Fn3 domain comprises non-naturally occurring loops.
- altered is meant one or more amino acid sequence alterations relative to a template sequence (i.e., the corresponding human fibronectin domain) and includes amino acid additions, deletions, and substitutions. Altering an amino acid sequence may be accomplished through intentional, blind, or spontaneous sequence variation, generally of a nucleic acid coding sequence, and may occur by any technique, for example, PCR, error-prone PCR, or chemical DNA synthesis.
- antibody-like proteins based on the 10 Fn3 scaffold can be defined generally by the following core amino acid sequence:
- the AB loop is represented by X a
- the CD loop is represented by X b
- the EF loop is represented by X c
- the BC loop is represented by X x
- the DE loop is represented by X y
- the FG loop is represented by X z .
- X represents any amino acid and the subscript following the X represents an integer of the number of amino acids.
- a may be anywhere from 1-15, 2-15, 1-10, 2-10, 1-8, 2-8, 1-5, 2-5, 1-4, 2-4, 1-3, 2-3, or 1-2 amino acids; and b, c, x, y and z may each independently be anywhere from 2-20, 2-15, 2-10, 2-8, 5-20, 5-15, 5-10, 5-8, 6-20, 6-15, 6-10, 6-8, 2-7, 5-7, or 6-7 amino acids.
- a is 2 amino acids
- b is 7 amino acids
- c is 7 amino acids
- x is 9 amino acids
- y 6 amino acids
- z is 12 amino acids.
- sequences of the beta strands may have anywhere from 0 to 10, from 0 to 8, from 0 to 6, from 0 to 5, from 0 to 4, from 0 to 3, from 0 to 2, or from 0 to 1 substitutions, deletions or additions across all 7 scaffold regions relative to the corresponding amino acids shown in SEQ ID NO: 1.
- the sequences of the beta strands may have anywhere from 0 to 10, from 0 to 8, from 0 to 6, from 0 to 5, from 0 to 4, from 0 to 3, from 0 to 2, or from 0 to 1 conservative substitutions across all 7 scaffold regions relative to the corresponding amino acids shown in SEQ ID NO: 1.
- the hydrophobic core amino acid residues are fixed and any substitutions, conservative substitutions, deletions or additions occur at residues other than the core amino acid residues.
- the BC, DE, and FG loops as represented by (X) x , (X) y , and (X) z , respectively, are replaced with polypeptides comprising BC, DE and FG loop sequences that bind to specific targets.
- Antibody-like proteins based on the 10 Fn3 scaffold can be defined generally by the sequence:
- the BC loop is represented by X x
- the DE loop is represented by X y
- the FG loop is represented by X z .
- X represents any amino acid and the subscript following the X represents an integer of the number of amino acids.
- x, y and z may each independently be anywhere from 2-20, 2-15, 2-10, 2-8, 5-20, 5-15, 5-10, 5-8, 6-20, 6-15, 6-10, 6-8, 2-7, 5-7, or 6-7 amino acids.
- x is 9 amino acids
- y is 6 amino acids
- z is 12 amino acids.
- sequences of the beta strands may have anywhere from 0 to 10, from 0 to 8, from 0 to 6, from 0 to 5, from 0 to 4, from 0 to 3, from 0 to 2, or from 0 to 1 substitutions, deletions or additions across all 7 scaffold regions relative to the corresponding amino acids shown in SEQ ID NO: 1.
- the sequences of the beta strands may have anywhere from 0 to 10, from 0 to 8, from 0 to 6, from 0 to 5, from 0 to 4, from 0 to 3, from 0 to 2, or from 0 to 1 conservative substitutions across all 7 scaffold regions relative to the corresponding amino acids shown in SEQ ID NO: 1.
- the core amino acid residues are fixed and any substitutions, conservative substitutions, deletions or additions occur at residues other than the core amino acid residues.
- the BC, DE, and FG loops as represented by (X) x , (X) y , and (X) z , respectively, are replaced with polypeptides comprising BC, DE and FG loop sequences that bind to specific targets.
- a 10 Fn3 domain as described herein may optionally contain a modified N- and/or C-terminal sequence.
- the 10 Fn3 domain may comprise an N-terminal extension and/or a C-terminal tail as described further below.
- the 10 Fn3 domain as shown in SEQ ID NO: 2 or 3 may optionally comprise an N-terminal extension of from 1-20, 1-15, 1-10, 1-8, 1-5, 1-4, 1-3, 1-2, or 1 amino acids in length.
- N-terminal extensions include (represented by the single letter amino acid code) M, MG, G, MGVSDVPRDL (SEQ ID NO: 17), VSDVPRDL (SEQ ID NO: 18), and GVSDVPRDL (SEQ ID NO: 19), or N-terminal truncations of any one of SEQ ID NOs: 17, 18 or 19.
- a Met-Gly sequence is added to the N-terminus of a 10 Fn3 domain, the M will usually be cleaved off, leaving a G at the N-terminus.
- the 10 Fn3 domain as shown in SEQ ID NO: 2 or 3 may optionally comprise a C-terminal tail of from 1-20, 1-15, 1-10, 1-8, 1-5, or 1-4 amino acids in length.
- tail sequences include, for example, polypeptides comprising, consisting essentially of, or consisting of, EIEK (SEQ ID NO: 5), EGSGC (SEQ ID NO: 10), EIEKPCQ (SEQ ID NO: 11), EIEKPSQ (SEQ ID NO: 26), EIEKP (SEQ ID NO: 27), EIEKPS (SEQ ID NO: 28), EIEKPC (SEQ ID NO: 12), EIDKPSQ (SEQ ID NO: 14), or EIDKPSQLE (SEQ ID NO: 16).
- the 10 Fn3 domain comprises a C-terminal tail comprising a sequence X(ED) n , wherein n is an integer from 2-10, 2-8, 2-5, 3-10, 3-8, 3-7, 3-5, 4-7, or wherein n is 2, 3, 4, 5, 6, 7, 8, 9 or 10, and X is optional, and when present is an E, I or EI.
- ED repeat tails may enhance solubility and/or reduce aggregation of the 10 Fn3 domain.
- the C-terminal tail comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 11.
- the C-terminal sequences lack DK sequences.
- the C-terminal tail comprises a residue that facilitates modification by PEG, i.e., a lysine or cysteine residue.
- the C-terminal tail lacks a DK sequence and comprises a cysteine residue.
- the fibronectin based scaffold proteins comprise a 10 Fn3 domain having both an N-terminal extension and a C-terminal tail.
- the fibronectin based scaffold protein is a multivalent protein that comprises two or more 10 Fn3 domains as described herein.
- a multivalent fibronectin based scaffold protein may comprise 2, 3 or more 10 Fn3 domains that are covalently associated.
- the fibronectin based scaffold protein is a bispecific or dimeric protein comprising two 10 Fn3 domains.
- a multivalent fibronectin based protein scaffold comprises a first 10 Fn3 domain that binds to a first target molecule and a second 10 Fn3 domain that binds to a second target molecule.
- the first and second target molecules may be the same or different target molecules.
- the 10 Fn3 domains i.e., the binding loops
- the first and second 10 Fn3 domains may be the same or different.
- they may bind to the same or different epitopes on the target.
- each 10 Fn3 domain of a multivalent fibronectin based protein scaffold binds to a desired target with a K D of less than 500 nM, 100 nM, 10 nM, 1 nM, 500 pM, 100 pM or less.
- each 10 Fn3 domain of a multivalent fibronectin based protein scaffold binds specifically to a target that is not bound by a wild-type 10 Fn3 domain, particularly the wild-type human 10 Fn3 domain.
- the 10 Fn3 domains in a multivalent fibronectin based scaffold protein may be connected by a polypeptide linker.
- exemplary polypeptide linkers include polypeptides having from 1-20, 1-15, 1-10, 1-8, 1-5, 1-4, 1-3, or 1-2 amino acids.
- Suitable linkers for joining the 10 Fn3 domains are those which allow the separate domains to fold independently of each other forming a three dimensional structure that permits high affinity binding to a target molecule.
- suitable linkers that meet these requirements comprise glycine-serine based linkers, glycine-proline based linkers, proline-alanine based linkers as well as the linker SEQ ID NO: 31.
- the linker is a glycine-serine based linker. These linkers comprise glycine and serine residues and may be between 8 and 50, 10 and 30, and 10 and 20 amino acids in length. Examples of such linkers include SEQ ID NOs: 32-36. In some embodiments, the linker is a glycine-proline based linker. These linkers comprise glycine and proline residues and may be between 3 and 30, 10 and 30, and 3 and 20 amino acids in length. Examples of such linkers include SEQ ID NOs: 37, 38 and 39.
- the linker is a proline-alanine based linker. These linkers comprise proline and alanine residues and may be between 3 and 30, 10 and 30, 3 and 20 and 6 and 18 amino acids in length. Examples of such linkers include SEQ ID NOs: 40, 41 and 42. It is contemplated, that the optimal linker length and amino acid composition may be determined by routine experimentation based on the teachings provided herein. In exemplary embodiments, the linker does not contain any DK sequences. In certain embodiments, the linker may be a C-terminal tail polypeptide as described herein, an N-terminal extension polypeptide as described herein, a linker polypeptide as described herein, or any combination thereof.
- a multivalent fibronectin based scaffold protein comprises two or more 10 Fn3 domains, wherein each domain comprises a C-terminal tail that does not contain a DK sequence.
- a multivalent fibronectin based scaffold protein comprises two or more 10 Fn3 domains, wherein each domain comprises a C-terminal tail that does not contain a DK sequence and at least one of the domains comprises a residue suitable for addition of a PEG moiety, such as a lysine or cysteine residue.
- PEG is a well-known, water soluble polymer that may be obtained commercially or prepared by ring-opening polymerization of ethylene glycol according to methods well known in the art (Sandler et al., Polymer Synthesis , Vol. 3, pp. 138-161, Academic Press, NY).
- the term “PEG” is used broadly to encompass any polyethylene glycol molecule, without regard to size or to modification at an end of the PEG, and can be represented by the formula:
- X—O(CH 2 CH 2 O) n-1 CH 2 CH 2 OH (1) where n is 20 to 2300 and X is H or a terminal modification, e.g., a C 1-4 alkyl.
- the PEG of the invention terminates on one end with hydroxy or methoxy, i.e., X is H or CH 3 (“methoxy PEG”).
- a PEG can contain further chemical groups which are necessary for binding reactions; which results from the chemical synthesis of the molecule; or which is a spacer for optimal distance of parts of the molecule.
- such a PEG can consist of one or more PEG side-chains which are linked together. PEGs with more than one PEG chain are called multiarmed or branched PEGs.
- Branched PEGs can be prepared, for example, by the addition of polyethylene oxide to various polyols, including glycerol, pentaerythriol, and sorbitol.
- a four-armed branched PEG can be prepared from pentaerythriol and ethylene oxide.
- Branched PEG are described in, for example, European Published Application No. 473084A and U.S. Pat. No. 5,932,462.
- One form of PEGs includes two PEG side-chains (PEG2) linked via the primary amino groups of a lysine (Monfardini, C. et al., Bioconjugate Chem., 6:62-69 (1995)).
- PEG conjugation to peptides or proteins generally involves the activation of PEG and coupling of the activated PEG-intermediates directly to target proteins/peptides or to a linker, which is subsequently activated and coupled to target proteins/peptides (see Abuchowski, A. et al., J. Biol. Chem., 252:3571 (1977) and J. Biol. Chem., 252:3582 (1977), Zalipsky et al. and Harris et al., in: Poly ( ethylene glycol ) Chemistry: Biotechnical and Biomedical Applications , Chapters 21 and 22, Harris, J. M., ed., Plenum Press, NY (1992)). It is noted that a polypeptide containing a PEG molecule is also known as a conjugated or PEGylated protein, whereas the protein lacking an attached PEG molecule can be referred to as unconjugated or free.
- PEG size of PEG utilized will depend on several factors including the intended use of the polypeptide. Larger PEGs are preferred to increase half life in the body, blood, non-blood extracellular fluids or tissues. For in vivo cellular activity, PEGs of the range of about 10 to 60 kDa are preferred, as well as PEGs less than about 100 kDa and more preferably less than about 60 kDa, though sizes greater than about 100 kDa can be used as well. For in vivo imaging applications, smaller PEGs, generally less than about 20 kDa, may be used that do not increase half life as much as larger PEGs so as to permit quicker distribution and less half life.
- a variety of molecular mass forms of PEG can be selected, e.g., from about 1,000 Daltons (Da) to 100,000 Da (n is 20 to 2300), for conjugating to polypeptides of the invention.
- the number of repeating units “n” in the PEG is approximated for the molecular mass described in Daltons. It is preferred that the combined molecular mass of PEG on an activated linker is suitable for pharmaceutical use. Thus, in one embodiment, the molecular mass of the PEG molecules does not exceed 100,000 Da.
- each PEG molecule has the same molecular mass of 12,000 Da (each n is about 270)
- the total molecular mass of PEG on the linker is about 36,000 Da (total n is about 820).
- the molecular masses of the PEG attached to the linker can also be different, e.g., of three molecules on a linker two PEG molecules can be 5,000 Da each (each n is about 110) and one PEG molecule can be 12,000 Da (n is about 270).
- one PEG moiety is conjugated to the polypeptide.
- the PEG moiety is about 30, 40, 50, 60, 70, 80, or 90 KDa.
- PEGylated polypeptides contain one, two or more PEG moieties.
- the PEG moiety(ies) are bound to an amino acid residue which is on the surface of the protein and/or away from the surface that contacts the target ligand.
- the combined or total molecular mass of PEG in a PEGylated polypeptide is from about 3,000 Da to 60,000 Da, from about 10,000 Da to 36,000 Da, or from about 35,000 Da to 45,000 Da, or about 40,000 Da.
- the PEG in a PEGylated polypeptide is a substantially linear, straight-chain PEG.
- PEG poly(ethylene glycol)
- a suitable molecular mass for PEG e.g., based on how the pegylated polypeptide will be used therapeutically, the desired dosage, circulation time, resistance to proteolysis, immunogenicity, and other considerations.
- a polypeptide is covalently linked to one poly(ethylene glycol) group of the formula: —CO—(CH 2 ) x —(OCH 2 CH 2 )— m —OR, with the —CO (i.e., carbonyl) of the poly(ethylene glycol) group forming an amide bond with one of the amino groups of the polypeptide; R being lower alkyl; x being 2 or 3; m being from about 450 to about 950; and n and m being chosen so that the molecular weight of the conjugate minus the polypeptide is from about 10 to 40 kDa.
- a polypeptide's ⁇ -amino group of a lysine is the available (free) amino group.
- carbonate esters of PEG are used to form the PEG-polypeptide conjugates.
- N,N′-disuccinimidylcarbonate (DSC) may be used in the reaction with PEG to form active mixed PEG-succinimidyl carbonate that may be subsequently reacted with a nucleophilic group of a linker or an amino group of a polypeptide (see U.S. Pat. Nos. 5,281,698 and 5,932,462).
- 1,1′-(dibenzotriazolyl)carbonate and di-(2-pyridyl)carbonate may be reacted with PEG to form PEG-benzotriazolyl and PEG-pyridyl mixed carbonate (U.S. Pat. No. 5,382,657), respectively.
- PEGylation of a polypeptide can be performed according to the methods of the state of the art, for example by reaction of the polypeptide with electrophilically active PEGs (supplier: Shearwater Corp., USA, www.shearwatercorp.com).
- Preferred PEG reagents of the present invention are, e.g., N-hydroxysuccinimidyl propionates (PEG-SPA), butanoates (PEG-SBA), PEG-succinimidyl propionate or branched N-hydroxysuccinimides such as mPEG2-NHS (Monfardini, C., et al., Bioconjugate Chem., 6:62-69 (1995)).
- PEG-SPA N-hydroxysuccinimidyl propionates
- PEG-SBA butanoates
- PEG-succinimidyl propionate or branched N-hydroxysuccinimides such as mPEG2-NHS (Monfardini
- PEG molecules may be coupled to sulfhydryl groups on a polypeptide (Sartore, L. et al., Appl. Biochem. Biotechnol., 27:45 (1991); Morpurgo et al., Bioconjugate Chem., 7:363-368 (1996); Goodson et al., Bio/Technology, 8:343 (1990); U.S. Pat. No. 5,766,897).
- U.S. Pat. Nos. 6,610,281 and 5,766,897 describe exemplary reactive PEG species that may be coupled to sulfhydryl groups.
- the pegylated polypeptide is produced by site-directed PEGylation, particularly by conjugation of PEG to a cysteine moiety at the N- or C-terminus.
- the polypeptide is an Fn3 domain covalently bound to a PEG moiety, wherein at least one of the loops of said Fn3 domain participates in binding to a target.
- the PEG moiety may be attached to the Fn3 polypeptide by site directed PEGylation, such as by attachment to a Cys residue, where the Cys residue may be positioned at the N-terminus of the Fn3 polypeptide or between the N-terminus and the most N-terminal beta or beta-like strand or at the C-terminus of the Fn3 polypeptide or between the C-terminus and the most C-terminal beta or beta-like strand.
- a Cys residue may be situated at other positions as well, particularly any of the loops that do not participate in target binding.
- a PEG moiety may also be attached by other chemistry, including by conjugation to amines.
- cysteine residues are native to the polypeptide, whereas in other embodiments, one or more cysteine residues are engineered into the polypeptide. Mutations may be introduced into a polypeptide coding sequence to generate cysteine residues. This might be achieved, for example, by mutating one or more amino acid residues to cysteine.
- Preferred amino acids for mutating to a cysteine residue include serine, threonine, alanine and other hydrophilic residues.
- the residue to be mutated to cysteine is a surface-exposed residue.
- Algorithms are well-known in the art for predicting surface accessibility of residues based on primary sequence or a protein.
- surface residues may be predicted by comparing the amino acid sequences of polypeptides, given that the crystal structure of the framework based on which polypeptides are designed and evolved has been solved (see Himanen et al., Nature, 414(6866):933-938 (Dec. 20-27, 2001)) and thus the surface-exposed residues identified.
- cysteine residues are introduced into polypeptides at or near the N- and/or C-terminus, or within loop regions.
- PEGylation of cysteine residues may be carried out using, for example, PEG-maleimide, PEG-vinylsulfone, PEG-iodoacetamide, or PEG-orthopyridyl disulfide.
- polypeptides are PEGylated on a cysteine residue using a maleimide linker.
- the pegylated polypeptide comprises a PEG molecule covalently attached to the alpha amino group of the N-terminal amino acid.
- Site specific N-terminal reductive amination is described in Pepinsky et al., J. Pharmacol. Exp. Ther., 297:1059 (2001), and U.S. Pat. No. 5,824,784.
- the use of a PEG-aldehyde for the reductive amination of a protein utilizing other available nucleophilic amino groups is described in U.S. Pat. No. 4,002,531, in Wieder et al., J. Biol. Chem., 254:12579 (1979), and in Chamow et al., Bioconjugate Chem., 5:133 (1994).
- pegylated polypeptide comprises one or more PEG molecules covalently attached to a linker, which in turn is attached to the alpha amino group of the amino acid residue at the N-terminus of the polypeptide.
- a polypeptide is PEGylated at the C-terminus.
- a protein is pegylated at the C-terminus by the introduction of C-terminal azido-methionine and the subsequent conjugation of a methyl-PEG-triarylphosphine compound via the Staudinger reaction.
- This C-terminal conjugation method is described in Cazalis et al., “C-Terminal Site-Specific PEGylation of a Truncated Thrombomodulin Mutant with Retention of Full Bioactivity”, Bioconjugate Chem., 15(5):1005-1009 (2004).
- a fibronectin based scaffold protein is pegylated in a C-terminal tail region as described further herein.
- exemplary C-terminal tails include, for example, a polypeptide having any one of SEQ ID NOs: 10, 11, or 12.
- a branched PEG moiety may be conjugated to a protein via a lone cysteine residue on the protein.
- the chemistry of this conjugation may be, for example, highly selective maleimide chemistry in which free electrons on the sulfhydryl group on the protein attach to the maleimide group on the PEG via Michael Addition ( FIG. 1 , where the protein is represented by R′ and PEG molecule is represented by R).
- the maleimide moiety forms a thioether bond with a sulfhydryl group on the protein.
- the Michael Addition reaction may be performed at a pH between pH 5.0 and pH 5.5 inclusive, or between pH 6.0 and 8.0 inclusive.
- the pegylated polypeptides will preferably retain at least about 25%, 50%, 60%, 70%, 80%, 85%, 90%, 95% or 100% of the biological activity associated with the unmodified protein.
- biological activity refers to its ability to bind to its target, as assessed by K D , k on or k off .
- the serum clearance rate of PEG-modified polypeptides may be decreased by about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or even 90%, relative to the clearance rate of the unmodified polypeptide.
- the PEG-modified polypeptide may have a half-life (t 1/2 ) which is enhanced relative to the half-life of the unmodified protein.
- the half-life of the PEG-polypeptide may be enhanced by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 125%, 150%, 175%, 200%, 250%, 300%, 400% or 500%, or even by 1000% relative to the half-life of the unmodified polypeptide.
- the protein half-life is determined in vitro, such as in a buffered saline solution or in serum. In other embodiments, the protein half-life is an in vivo half life, such as the half-life of the protein in the serum or other bodily fluid of an animal.
- a PEGylated polypeptide has a shelf-life of at least 6 months, 1 year, 2 years, 3 years, 4 years, 5 years or more when formulated at a pH between pH 2.0 and pH 6.0 (e.g., a pH between pH 3.0 and 5.0).
- FBSP-P An exemplary fibronectin-based scaffold protein is FBSP-P, which is a mono-ADNECTINTM having high affinity binding to PCSK9.
- FBSP-P is conjugated to a 40 kDa branched PEG via a lone cysteine residue on the protein.
- An initial pH range of 6.0 to 7.5 was examined since, at the time, a neutral pH was thought to be desirable for the subcutaneous administration of the product.
- FIG. 2 An example of the RP-HPLC results can be seen in FIG. 2 . Samples were run on a Polymer Labs PLRP-S column, 2.0*150 mm, with a column temperature of 40° C. and an H 2 O/ACN/TFA gradient. Dual detection was performed with UV and Evaporative Light Scattering (ELS), which measures a relative quantification of protein-related impurities by UV signal and quantifies free PEG species by ELS signal using a PEG calibration curve.
- ELS Evaporative Light Scattering
- FBSP-P showed no clipping along its protein backbone due to the substitution of the aspartic acid in the C-terminal tail region with a glutamic acid at the position corresponding to amino acid residue 97 of SEQ ID NO: 47 (i.e., a DK-construct). Although several other aspartic acid residues exist in the protein sequence, these did not lead to clipping and only the fragment peaks identified in FIG. 3 and Table 1 were consistently observed during formulation development and stability.
- FBSP-V is an ADNECTINTM that binds to VEGFR2 with high affinity and having the sequence of SEQ ID NO: 48.
- FBSP-V is conjugated to a 40 kDa branched PEG moiety via a lone cysteine residue at position 93 of SEQ ID NO: 48.
- DePEGylation of FBSP-V was evaluated using a set of formulations ranging from pH 4.5 to 6.5.
- Table 3 indicates this trend in regard to total pre-peaks; however, as the pH increases, the % of intact free ADNECTINTM increases, which was the same trend as that observed in FBSP-P as described in Example 1.
- FBSP-V/I Another exemplary fibronectin-based scaffold protein is FBSP-V/I, a multivalent polypeptide with high affinity to VEGFR2 and IGF-IR.
- FBSP-V/I comprises the amino acid sequence of SEQ ID NO: 9, and contains a single 40 kDa branched PEG conjugated to the cysteine at position 203 of SEQ ID NO:9.
- FIG. 10 Characterization of a stressed FBSP-V/I sample is shown in FIG. 10 .
- the results demonstrate, among various protein clips, the existence of the intact free (unPEGylated) FBSP-V/I ADNECTINTM in the des Met form with oxidation (+32). The dimeric form of the same species can also be seen.
- FIG. 11 shows a comparison of dePEGylation of several ADNECTINSTM, as a measure of free PEG over the course of 1-4 weeks.
- the exemplary ADNECTINSTM are FBSP-P (samples F1, F2, and F3) stored at pH 6.0; FBSP-V/I stored at pH 5.5; FBSP-V stored at pH 5.0; and FBSP-E/I stored at pH 4.0.
- FBSP-E/I is a multivalent polypeptide comprising two 10 Fn3 domains with the BC, DE and FG loops altered such that one 10 Fn3 domain binds with high affinity to EGFR and the other 10 Fn3 domain binds with high affinity to IGF-IR.
- the preferred pH range for conjugation through maleimide chemistry is 6.5 to 7.5, and in the past the PEGylation step for ADNECTINSTM has been conducted at pH 5 to 5.5 using the PEG in solid form.
- PEG solutions were prepared using MILLI-Q® water (pH ⁇ 5.5) and 50 mM Tris (pH 7.0). The solutions were stressed at 37° C. for one week, and their functionality was assessed through a PEGylation reaction with the FBSP-V free ADNECTINTM. The pH 7 solution was pH adjusted to ⁇ 5.5 prior to the reaction for a more direct comparison to the PEG in water.
- Table 4 shows that, after stress, some of the maleimide functional group on the PEG was lost in the pH 5.5 solution and that the functionality was completely lost in the pH 7.0 solution.
- Total pre-peaks refers to all pre-peaks detected before the elution of FBSP-V product including all clips and intact FBSP-V free species; “free FBSP-V free ADNECTIN TM” refers to the sum of free (unPEGylated) FBSP-V free ADNECTIN TM and FBSP-V free dimer.
- FBSP-P Two lots of FBSP-P (lots 1 and 2) were used in two separate pH studies covering the range of pH 4 to 7.5, at half pH unit intervals.
- the samples were formulated using the high throughput formulation format on a TECAN® robot.
- the drug substance (10 mg/mL, in 10 mM succinate, pH 6.0) was mixed with concentrates of succinate buffers (from pH 4 to 7.5) and sorbitol, which resulted in a final protein concentration of 1 mg/mL or 10 mg/mL in the excipients and pH described in the results section.
- the samples were put on stability in 96-well plate format and tested directly out of the plates.
- the FBSP-V/I sample was formulated using tangential flow filtration (TFF), filled in vials and subject to stability testing as described herein.
- TFF tangential flow filtration
- RP-UV-ELSD RP-UV-ELSD.
- a PLRP-S column (4.6*150 mm, Polymer Labs) was used for the analysis of FBSP-P samples.
- the protein fragments were analyzed on a relative percent basis at 280 nm using UV detection, and the free PEG moiety was quantified on a mole % basis using a 5-point PEG calibration curve with evaporative light scattering (ELS) detection.
- ELS evaporative light scattering
- the method utilizes a water/acetonitrile/trifluoroacetic acid gradient.
- the HPLC method using the Jupiter C18 column was coupled to a Thermo LTQ ion trap mass spectrometer, and the flow was split after the UV detector with 0.2 mL/min introduced into the ionization source of the MS.
- the MS data obtained was deconvoluted using the MagTran software, and structures were assigned to the detected masses using the PAWS software.
- FBSP For expression of FBSP, a nucleotide sequence encoding the construct is cloned into an inducible expression vector and is expressed in E. coli cells (either as a soluble fraction or into intracellular inclusion bodies).
- E. coli cells either as a soluble fraction or into intracellular inclusion bodies.
- Cell bank vials generated from a culture of a single plated colony are used to inoculate a shake flask culture as an inoculum for a large-scale fermentor.
- a seed fermentor is used for an inoculum culture, depending on the final fermentation volume.
- the large-scale fermentation contains a growth phase to accumulate biomass and a production phase to generate the FBSP.
- insoluble FBSP intracellular inclusion bodies are released from harvested cells using a MICROFLUIDIZER® and recovered by centrifugation, followed by washes with buffer and water.
- the purification process for insoluble FBSP uses a Guanidine-HCl based resolubilization of inclusion bodies, followed by refolding the protein.
- soluble FBSP For soluble FBSP, cells were pelleted and lysed using a MICROFLUIDIZER® and the soluble fraction was recovered by centrifugation, and the supernatant was clarified by filtration.
- the protein is then purified using one or more columns, such as a HISTRAP® column, a cation exchange chromatography column, and/or a hydrophobic interaction column.
- the resulting purified FBSP is then covalently linked to a PEG via maleimide chemistry at a single cysteine residue to produce PEGylated protein.
- the PEGylated protein may then be purified over one or more additional columns, such as a cation exchange chromatography column.
- the elution is concentrated to a target protein concentration and then exchanged into the formulation buffer using ultrafiltration/diafiltration (UF/DF).
- UF/DF ultrafiltration/diafiltration
- the UF/DF product is filtered using a final 0.22 ⁇ m filter.
- the filtered product is then filled into vials to produce the final product.
- This Example shows that dePEGylation at neutral or alkaline pH occurs not only with polypeptides and proteins, but also with smaller peptides. This Example also shows that dePEGylation occurs regardless of the type of linker connecting the PEG moiety to the peptide and regardless of the type of PEG.
- the structures of the three PEG-MALs are described below:
- the samples were analyzed for dePEGylation by RP-HPLC.
- a Polaris C8-A column (2.1*150 mm, VARIAN®) was used for the analysis of PEGylated peptide samples.
- the free peptide was quantified on a relative percent basis to the intact sample at 214 nm using UV detection.
- the method utilizes a water/acetonitrile/trifluoroacetic acid gradient. For peak identification, LC-MS was conducted.
- the results, which are shown in FIGS. 13 , 14 and 15 , indicate that a higher level of dimerized free peptide was observed in each of the 3 stressed samples relative to the level in each of the samples at T 0.
- the bar graph in FIG. 15 demonstrates an increase in the relative level of the free peptide, in the form of a covalent dimer, for all three conjugated peptides after heat stress.
- the free peptide generated formed a covalent dimer due to the free cysteine now available as a result of dePEGylation, which was confirmed by MS and MS/MS analysis.
- the fact that the level of the covalent dimer increased after heat stress further indicates that the dePEGylation event regenerated an intact free peptide containing a free cysteine residue.
- a low level of the free peptide was present at T0 for all three samples due to its incomplete removal with the PD-10 column purification. However, a measurable increase in the level of the free peptide was still observed.
- the results indicate that dePEGylation can also occur with a short peptide (i.e., not only with a larger polypeptide or protein). Moreover, the results show that dePEGylation is not greatly affected by the length of the alkyl linker, nor by the branching structure in the PEG-MAL, as all three samples underwent dePEGylation to a similar extent.
- This Example shows that less dePEGylation of a small PEGylated peptide occurs at lower pH relative to higher pH.
- a synthetic peptide consisting of the amino acid sequence TEIDKPCQ (SEQ ID NO: 48) was conjugated to a 2kPEG-MAL. Briefly, the peptide was solubilized in NaOAc at pH 5.5. PEG in water was added to the peptide and the conjugation reaction occurred overnight. The sample was cleaned up via buffer exchange over PD-10 columns into pH 8.0 Tris or pH 5.5 NaOAc. The two samples were stressed at 37° C. for one week, followed by analysis using RP-HPLC, as described in Example 5.
- results which are shown in FIG. 16 , indicate that, similarly to larger polypeptides, smaller peptides are subject to less dePEGylation at lower pH, compared to higher pH.
- This Example shows that reducing the pH reduces dePEGylation of proteins regardless of whether they contain a large PEG, a small PEG, a branched PEG or a linear PEG.
- C7 protein (SEQ ID NO: 48), was conjugated to a variety of PEG-MALs with different molecular weights, including 2 k, 5 k, 10 k, 12 k, 20 k, 20 k bis (bi-functional), 30 k and 40 k branched (NOF America Corp.). Each sample was purified over an ion-exchange column, then formulated in 50 mM sodium acetate at pH 4.5 or 50 mM Tris at pH 8.0. The samples were heat stressed at 37° C. for one week and the results were measured by RP-HPLC using a Jupiter C18 column (4.6*250 mm, PHENOMENEX®). The protein fragments were quantified on a relative percent basis to the intact sample at 280 nm using UV detection. The method utilizes a water/acetonitrile/trifluoroacetic acid gradient. For peak identification, LC-MS was conducted.
- results which are shown in FIG. 17 , indicate a substantially higher level of dePEGylation after the heat stress in the samples at pH 8.0 relative to the samples at pH 5.5.
- results also indicate no difference in the level of degradation among the different sizes of PEG-MALs used in the conjugation.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Described herein are methods for maintaining PEGylation and inhibiting dePEGylation of polypeptides, such as fibronectin-based scaffold proteins, during storage.
Description
- This application claims priority to U.S. Provisional application No. 61/487,027 filed on May 17, 2011, the contents of which are specifically incorporated by reference herein.
- PEGylation is a process by which polyethylene glycol (PEG) polymer chains are covalently conjugated to other molecules such as drugs or proteins. This chemical modification confers on the conjugate molecules many of the properties of PEG polymers, including hydrophilicity, structural flexibility, high mobility in solution, and low toxicity. With these new properties, PEGylated therapeutic agents show improved efficacy as compared to their unconjugated counterparts, due to increased serum half life, water solubility, protection from proteolytic degradation, low immunogenicity, and/or stability of the PEGylated molecules.
- It is generally desirable to maintain therapeutic agents in a PEGylated state, particularly when drugs are manufactured and stored for a period of time before use. However, PEGylation is a reversible reaction and dePEGylation has been observed during formulation development, stability monitoring, and storage of some therapeutic proteins. This creates a heterogeneous mixture of PEGylated and dePEGylated molecules, which may lose efficacy, safety, and other benefits of PEGylation. Accordingly, there remains a need for maintaining PEGylation of therapeutic molecules during storage of these molecules.
- The present invention relates to methods for maintaining the PEGylation state of PEGylated polypeptides during periods of storage. Disclosed herein are compositions comprising a polypeptide conjugated to a PEG moiety through a maleimide linker, wherein the composition has a pH between pH 2.0 and pH 6.0. The composition may have a pH between pH 3.0 and pH 5.0. The composition may have a pH between pH 3.5 and pH 4.5. In certain embodiments, less than 5% of the maleimide linkers are cleaved over a 4, 8, 12 or more week storage period. The polypeptide may comprise a domain or region that binds specifically to a target protein, such as a tenth fibronectin type III (10Fn3) domain having an altered amino acid sequence relative to the wild-type sequence that binds to a target molecule with a KD of less than 500 nM. The 10Fn3 domain may comprise at least one loop region that differs from a naturally occurring loop region and at least one beta strand that differs from the naturally occurring beta strand. In certain embodiments, the 10Fn3 domain does not contain a DK sequence in the C-terminal tail region. The C-terminal tail of the 10Fn3 domain may comprise a cysteine residue, to which the PEG moiety is linked. In certain embodiments, less than 1% of the maleimide linkers are cleaved over a four week storage period. The polypeptide may further comprise a second 10Fn3 domain having an altered amino acid sequence relative to the wild-type sequence that binds to a target molecule with a KD of less than 500 nM. The first and second 10Fn3 domains may bind to different targets. The first and second 10Fn3 domains may be connected by a polypeptide linker comprising from 1-30 amino acids. The polypeptide linker may be selected from the group consisting of: a glycine-serine linker, a glycine-proline linker, a proline-alanine linker and an Fn linker. The maleimide linker may form a thioether bond with a sulfhydryl group on the polypeptide. The 10Fn3 domain may comprise at least two loop regions that differ from the corresponding naturally occurring loop regions. An exemplary composition comprises a polypeptide conjugated to a PEG moiety through a maleimide linker, wherein the composition has a pH between pH 3.0 and pH 5.0 and wherein (i) the polypeptide comprises a 10Fn3 domain having an altered amino acid sequence relative to the wild-type sequence that binds to a target molecule with a KD of less than 500 nM; (ii) the 10Fn3 domain comprises at least one loop region that differs from the naturally occurring corresponding loop region and at least one beta strand that differs from the naturally occurring corresponding beta strand; (iii) the 10Fn3 domain does not contain a DK sequence in the C-terminal tail region; and the 10Fn3 domain comprises a cysteine residue, to which the PEG moiety is linked. In certain embodiments, less than 5% of the maleimide linkers are cleaved over a four week storage period.
- Further disclosed herein are methods for maintaining PEGylation of polypeptides during storage by storing the polypeptides in a solution buffered to a pH between 2.0-6.0, 2.0-5.0, 2.0-4.0, 2.0-3.0, 3.0-6.0, 3.0-5.0, 3.0-4.0, 3.5-4.5, 4.0-5.0, 4.5-5.5, or 5.0-6.0. The polypeptides are conjugated to a polyethylene glycol (PEG) moiety through a maleimide linker. The maleimide linker may connect the PEG moiety to the polypeptide via a thioether bond with a sulfhydryl group on the polypeptide. In exemplary embodiments, less than 25%, 20%, 15%, 10%, 5%, 2%, 1%, 0.5%, 0.2% or 0.1% of the maleimide linkers are cleaved over a storage period of at least four weeks, eight weeks, six months, or one year.
- In certain embodiments, the PEGylated polypeptides comprise a tenth fibronectin type III (10Fn3) domain having an altered amino acid sequence relative to the wild-type sequence that binds to a target molecule with a KD of less than 500 nM. The 10Fn3 domain may have a C-terminal tail that does not contain a DK sequence, which has been found to be susceptible to cleavage in certain instances at pHs below 6.0. The 10Fn3 domain may contain a cysteine residue that serves as the site for attachment of the PEG moiety, preferably in the C-terminal tail region.
- In certain embodiments, the PEGylated polypeptides are a multivalent polypeptide comprising two or more 10Fn3 domains. Each 10Fn3 domain may comprise an altered amino acid sequence relative to the wild-type sequence such that it binds to a target molecule with a KD of less than 500 nM. The first and second 10Fn3 domains bind to the same or different targets. The first and second 10Fn3 domains may be connected by a polypeptide linker comprising from 1-30 amino acids. Exemplary polypeptide linkers include, for example, a glycine-serine linker, a glycine-proline linker, a proline-alanine linker or an Fn linker.
- In exemplary embodiments, the PEGylated polypeptides are stored in a formulation comprising (a) 25 mM succinate, 5% sorbitol; (b) 10 mM sodium acetate, 5% mannitol; or (c) 10 mM sodium acetate/2% mannitol, 100 mM sodium chloride.
- In certain embodiments, the concentration of PEGylated polypeptides in the storage solution is from 1-10 mg/mL, 1-5 mg/mL, 0.5-2 mg/mL, or 4-6 mg/mL, or is about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mg/mL.
- In certain embodiments, the methods involve storing the PEGylated polypeptides at a temperature from 4-30° C., 4-25° C., 4-15° C., 4-10° C., 10-30° C., or 10-25° C., or at 4, 10, 15, 20, 25 or 30° C.
- In another aspect, the application provides a method for improving the stability of PEGylated polypeptides in a solution, wherein the polypeptides are conjugated to a polyethylene glycol (PEG) moiety through a maleimide linker, comprising the steps of: (a) determining the amount of PEG cleaved from the polypeptides over a fixed storage period in the solution; and (b) if PEG is cleaved from more than 5% of the polypeptides over the storage period, reformulating the PEGylated polypeptides in a storage solution buffered to a pH of between 2.0-6.0.
-
FIG. 1 illustrates the mechanism of Michael Addition, showing the ligation between a protein (R′) via its sulfhydryl group and the PEG molecule (R). -
FIG. 2A-B shows the RP-HPLC profile of a FBSP-P stability sample (10 mg/mL, formulated in 10 mM succinate, 5% (w/v) sorbitol, 1.2% (w/v) alanine, pH 6.0; incubated at 25° C. for four weeks). A: UV trace at 280 nm depicting the detection of free (unPEGylated) FBSP-P ADNECTIN™. B: ELSD trace showing the detection of free intact PEG. -
FIG. 3 shows UV (280 nm) profile of a FBSP-P stability sample (1 mg/mL, formulated in 25 mM succinate, 1% glycine, pH 7.5; incubated at 25° C. for two weeks) from an LC-MS analysis. -
FIG. 4 presents a graph showing an increase in mole % of free PEG in FBSP-P samples formulated at different pH, during 25° C. stability testing for two weeks. Protein was formulated at 1 mg/mL in 25 mM succinate, 5% (w/v) sorbitol, at the pH indicated. -
FIG. 5 is a graph showing an increase in mole % of free PEG in FBSP-P samples formulated at different pH, during 37° C. stability testing for two weeks. Protein was formulated at 1 mg/mL in 25 mM succinate, 5% (w/v) sorbitol, at the pH indicated. -
FIG. 6A-B shows the increase in % free (unPEGylated) ADNECTIN™ in FBSP-P samples formulated at different pH, during 25° C. stability testing for two weeks. Free ADNECTIN™ refers to the sum of both the monomeric and dimeric form of the unPEGylated protein. Protein was formulated at 1 mg/mL in 25 mM succinate, 5% (w/v) sorbitol, at the pH indicated. -
FIG. 7 shows the increase in % free (unPEGylated) ADNECTIN™ in FBSP-P samples formulated at different pH, during 37° C. stability testing for two weeks. Free ADNECTIN™ refers to the sum of both the monomeric and dimeric form of the unPEGylated protein. Protein was formulated at 1 mg/mL in 25 mM succinate, 5% (w/v) sorbitol, at the pH indicated. -
FIG. 8A-D is a series of UV profiles (at 280 nm) of FBSP-V stressed samples at different pH values, obtained from LC-MS analysis. FBSP-Vfree refers to the free (unPEGylated) ADNECTIN™ of FBSP-V. Only the pre-peak region of the UV profile is shown. All samples (10 mM sodium acetate, 5% mannitol) were stressed at 25° C. for a period of 6 months.FIG. 8A shows the UV profile of a sample at 5 mg/mL protein concentration, pH 4.5.FIG. 8B shows the UV profile of a sample at 5 mg/mL, pH 5.5.FIG. 8C shows the UV profile of a sample at 5 mg/mL, pH 6.5.FIG. 8D shows the UV profile a sample at 10 mg/mL, 10 mM NaOAc, 5% mannitol, pH 6.5. -
FIG. 9 illustrates the results of non-reduced SDS-PAGE analysis of FBSP-V stability samples at T=0 and T=6 months at 25°C. Lanes Lanes Lanes Lanes -
FIG. 10 is the UV profile (280 nm) of a stressed FBSP-V/I sample (10 mM acetate, 150 mM sodium chloride, pH 5.5, 5 mg/mL; 25 C for 4 weeks). Peak assignments shown were based on LC-MS analysis. -
FIG. 11 shows a comparison of dePEGylation in several ADNECTINS™, as a measure of free PEG over the course of 1-4 weeks. The exemplary ADNECTINS™ are FBSP-P (samples F1, F2, and F3) stored at pH6.0; FBSP-V/I stored at pH 5.5 (VI); FBSP-V stored at pH 5.0 (V); and FBSP-E/I stored at pH 4.0 (EI). -
FIG. 12 shows the structure of a 2-branched PEG-MAL with a C2 alkyl linker, conjugated to a protein through cysteine residue. -
FIG. 13 shows HPLC profiles of a synthetic peptide conjugated to three different 40 kD PEG-MALs in a composition at pH 8.3 and at T=0. The profiles from top to bottom are those of: (1) free peptide; (2) peptide conjugated to ME-400MA (C2 linker) linear PEG; (3) peptide conjugated to GLE-400MA3 (C5 linker) 2-branched PEG; and peptide conjugated to GLE-400MA (C2 linker) 2-branched PEG. -
FIG. 14 shows HPLC profiles of a synthetic peptide conjugated to three different 40 kD PEG-MALs in a composition at pH 8.3 (same as inFIG. 13 ), after one week at 37° C. The profiles from top to bottom are those of: (1) free peptide; (2) peptide conjugated to ME-400MA (C2 linker) linear PEG; (3) peptide conjugated to GLE-400MA3 (C5 linker) 2-branched PEG; and peptide conjugated to GLE-400MA (C2 linker) 2-branched PEG. -
FIG. 15 shows the percentage of free peptide observed in samples of a peptide conjugated to three different 40 kD PEG-MALs in compositions at pH 8.3, at T0 and T=1 week after heat stress at 37° C. (histogram based on results shown inFIGS. 13 and 14 ). -
FIG. 16 shows HPLC profiles of samples of PEGylated peptides at pH 5.5 or pH 8.0 at T=0 or after 1 week at 37° C. -
FIG. 17 is a histogram showing the increased percentage of free C7 protein derived from PEGylated C7 proteins after one week of heat stress of the PEGylated C7 proteins at 37° C. relative to T0, comparing samples formulated in pH 4.5 sodium acetate and pH 8.0 Tris. - The methods of the present application may be used to maintain a polyethylene glycol (PEG) moiety on PEGylated conjugates, particularly protein or peptide therapeutics, during manufacture and/or storage of the PEGylated conjugates. These methods have broad applicability to proteins and peptides that have been PEGylated to overcome issues with stability, degradation, clearance, and tolerance in subjects. The process of PEGylation links polyethylene glycol chains to candidate therapeutics to produce larger conjugates that show improved efficacy as compared to their unconjugated counterparts, due to increased serum half life, increased solubility, increased protection from proteolytic degradation, reduced immunogenicity, and/or increased stability of the PEGylated molecules.
- The present application describes methods to preserve PEGylation and all of its associated benefits and methods to inhibit dePEGylation of PEGylated conjugates. Specifically, the application provides methods to inhibit cleavage of PEG moieties conjugated to polypeptides through a maleimide linker by formulating and storing the PEGylated polypeptides in a solution buffered to a pH value between pH 2.0 and pH 6.0. The methods described herein are based on the observation that certain PEGylated conjugates are subject to significant cleavage of the PEG moiety from the polypeptide resulting in regeneration of the free (unPEGylated) polypeptide and formation of protein aggregates and/or disulfide-linked polypeptide dimers. It was observed that the amount of dePEGylation depended on the pH of the formulation, and that formulations with higher pHs led to higher levels of dePEGylation. As dePEGylation has been found to be most prominent at higher pH (≧6), the present methods inhibit dePEGylation by maintaining PEGylated polypeptide conjugates at a pH below 6.0. Notably, the methods may apply to PEGylated polypeptides that are conjugated to PEG through a maleimide moiety.
- By a “polypeptide” is meant any sequence of two or more amino acids, regardless of length, post-translation modification, or function. “Polypeptide”, “peptide”, and “protein” are used interchangeably herein. Polypeptides can include natural amino acids and non-natural amino acids such as those described in U.S. Pat. No. 6,559,126, incorporated herein by reference. Polypeptides can also be modified in any of a variety of standard chemical ways (e.g., an amino acid can be modified with a protecting group; the carboxy-terminal amino acid can be made into a terminal amide group; the amino-terminal residue can be modified with groups to, e.g., enhance lipophilicity; or the polypeptide can be chemically glycosylated or otherwise modified to increase stability or in vivo half-life). Polypeptide modifications can include the attachment of another structure such as a cyclic compound or other molecule to the polypeptide and can also include polypeptides that contain one or more amino acids in an altered configuration (i.e., R or S; or, L or D).
- “Percent (%) amino acid sequence identity” herein is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in a selected sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN, ALIGN-2 or Megalign (DNASTAR®) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full-length of the sequences being compared. For purposes herein, however, % amino acid sequence identity values are obtained as described below by using the sequence comparison computer program ALIGN-2. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc. has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087, and is publicly available through Genentech, Inc., South San Francisco, Calif. The ALIGN-2 program should be compiled for use on a UNIX operating system, preferably digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.
- For purposes herein, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows: 100 times the fraction X/Y where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A.
- The “half-life” of a polypeptide is the time taken for the concentration of the polypeptide to fall to half its original value. The “serum half-life” of a polypeptide can generally be defined as the time taken for the serum concentration of the polypeptide to be reduced by 50%, in vivo, for example due to degradation of the polypeptide and/or clearance or sequestration of the polypeptide by natural mechanisms. The half-life can be determined in any manner known per se, such as by pharmacokinetic analysis. Suitable techniques for determining half-life, e.g., serum half-life, will be clear to the person skilled in the art, and may, for example, generally involve the steps of administering a suitable dose of a polypeptide to a primate; collecting blood samples or other samples from said primate at regular intervals; determining the level or concentration of the polypeptide in said blood sample; and calculating, from (a plot of) the data thus obtained, the time until the level or concentration of the polypeptide has been reduced by 50% compared to the initial level upon dosing. Methods for determining half-life may be found, for example, in Kenneth et al., Chemical Stability of Pharmaceuticals: A Handbook for Pharmacists (1986); Peters et al., Pharmacokinetic Analysis: A Practical Approach (1996); and Gibaldi, M. et al., Pharmacokinetics, 2nd Rev. Edition, Marcel Dekker (1982).
- Half-life can be expressed using parameters such as the t1/2-alpha, t1/2-beta and the area under the curve (AUC). In the present specification, an “increase in half-life” refers to an increase in any one of these parameters, any two of these parameters, or in all three these parameters. In certain embodiments, an increase in half-life refers to an increase in the t1/2-beta, either with or without an increase in the t1/2-alpha and/or the AUC or both.
- “Shelf-life” of a pharmaceutical product e.g., a PEGylated polypeptide, is the length of time the product is stored before decomposition occurs. For example, shelf-life may be defined as the time for decomposition of 0.1%, 0.5%, 1%, 5%, or 10% of the product.
- A “purified” polypeptide or PEGylated polypeptide is preferably at least 85% pure, more preferably at least 95% pure, and most preferably at least 98% or 99% pure. Regardless of the exact numerical value of the purity, the polypeptide or PEGylated polypeptide is sufficiently pure for use as a pharmaceutical product.
- Given the benefits of PEGylation, it is clear that dePEGylation of PEG-protein conjugates is undesirable in many situations. DePEGylation is defined as the loss of at least one PEG moiety from a PEGylated conjugate molecule, resulting in the regeneration of the intact free polypeptide and the intact free PEG moiety. This reaction may result in decreased bioavailability, decreased blood circulation, increased immunogenicity, and decreased efficacy of a therapeutic agent, as compared to its PEGylated form. Following dePEGylation, the free polypeptides may undesirably form dimers or aggregates. For example, when the PEG molecules are attached to cysteine residues on protein molecules, dePEGylation exposes free cysteine residues that could interact with one another through intermolecular disulfide linkages to form protein dimers. Alternatively, dePEGylation may result in exposure of hydrophobic surfaces that could lead to protein aggregation.
- DePEGylation may be measured using methods known in the art, such as reverse phase high performance liquid chromatography (RP-HPLC). Dual absorbance detectors may be used, for example, UV absorbance may be used for the detection of polypeptide species, while an evaporative light scattering detector (ELSD) may be used to detect the PEG moieties. In addition, liquid chromatograph-mass spectrometry (LC-MS) may be used to determine the amount of free protein molecules as well as characterize the form of the free protein as monomers, dimers, or aggregates. RP-HPLC may be used to characterize the integrity of the free PEG released from the conjugate using retention time of the released PEG as compared to the retention time for a PEG standard. For those PEGylated conjugates that were generated by maleimide chemistry, the free PEG produced by dePEGylation of the conjugate may contain the maleimide functional group.
- Factors which affect PEGylation include, but are not limited to, conditions of the original PEGylation reaction, length of storage of the PEGylated molecules, storage temperature, composition of the buffers and/or solutions in which the molecules are made and/or stored, pH of the storage buffers and/or solutions, and identity of the proteins that have been conjugated to PEG.
- In some embodiments of the present application, PEGylation is maintained by storing the PEGylated polypeptides in a solution buffered to a pH value between pH 2.0 and pH 6.0. In some embodiments, the PEGylated polypeptides are stored in a solution buffered to a pH value between pH 2.0-6.0, 2.0-5.0, 2.0-4.0, 2.0-3.0, 2.0-2.5, 3.0-6.0, 3.0-5.0, 3.0-4.0, 3.0-3.5, 4.0-6.0, 4.0-5.0, 4.0-4.5, 2.5-3.5, or 2.5-3.5. In some embodiments, the PEGylated polypeptides are stored in a solution buffered to a pH of 4.0, 4.5, 5.0, 5.5, or 6.0.
- Suitable formulations for storing PEGylated polypeptides in accordance with the methods described herein are pharmaceutically acceptable compositions comprising a PEGylated polypeptide as described herein, wherein the composition is essentially endotoxin or pyrogen free. Formulations to be used for in vivo administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes.
- Therapeutic formulations comprising PEGylated polypeptides are prepared for storage by mixing the PEGylated polypeptides having the desired degree of purity with optional physiologically acceptable carriers, excipients or stabilizers (Osol, A., ed., Remington's Pharmaceutical Sciences, 16th Edition (1980)), in the form of aqueous solutions, lyophilized or other dried formulations. Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, sodium acetate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyidimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as alanine, glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrans; chelating agents such as EDTA; sugars or sugar alcohols such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g., Zn-protein complexes); and/or non-ionic surfactants such as Tween, PLURONIC® or polyethylene glycol (PEG).
- Suitable solutions for storing the PEGylated polypeptides generally contain from 1-100 mM, 10-100 mM, 25-100 mM, 50-100 mM, 1-50 mM, 1-25 mM, 1-10 mM, 10-50 mM 10-25 mM, 10-20 mM, 10-15 mM of a buffering agent. In certain embodiments, the solutions for storing the PEGylated polypeptides contain 10 mM buffer or 25 mM of a buffering agent. Exemplary buffering agents include, for example, citrate, histidine, succinate or sodium acetate.
- Exemplary formulations for storing PEGylated polypeptides may be selected from (a) 25 mM succinate, 5% sorbitol; (b) 10 mM sodium acetate, 5% mannitol; and (c) 10 mM sodium acetate/2% mannitol, 100 mM sodium chloride.
- In certain embodiments, the concentration of PEGylated polypeptide in a formulation for storage ranges from 0.5-15 mg/mL, 0.5-5 mg/mL, 0.5-2 mg/mL, 1-10 mg/mL, 1-5 mg/mL, 1-2 mg/Ml, 3-10 mg/mL, 3-8 mg/mL, 3-6 mg/mL, 3-5 mg/mL, 4-10 mg/mL, 4-8 mg/mL, 4-6 mg/mL, 5-10 mg/mL, 5-8 mg/mL, or 5-6 mg/mL. In other embodiments, the concentration of PEGylated polypeptide in a formulation for storage may be about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 mg/mL.
- In certain embodiments, the methods described herein may be used to maintain PEGylation and/or inhibit dePEGylation of polypeptides having one, two, three, four or more PEG moieties per polypeptide molecule. In exemplary embodiments, the methods described herein are used in connection with PEGylated polypeptides having only a single PEG per polypeptide.
- Formulations of PEGylated polypeptides may be suitable for administration via any desirable route. For example, the formulations may be suitable for administration intravenously as a bolus or by continuous infusion over a period of time, by intramuscular, subcutaneous, intra-articular, intrasynovial, intrathecal, oral, topical, or inhalation routes.
- In certain embodiments, at least 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% of PEGylation is maintained for at least 2 weeks, 4 weeks, 3 months, 6 months, 1 year or more. PEGylation may also be maintained for over 1 year, or for as long as the activity of the PEGylated conjugate remains at therapeutically effective levels. There percentage of PEGylation maintained is determined relative to the initial level of PEGylation of the PEGylated polypeptide. For example, at least 98% of PEGylation is maintained for a two week period if less than 2% of the polypeptides have lost a PEG moiety after storage for two weeks as compared to the level of PEGylation at time zero.
- The methods described herein may involve maintaining PEGylation during storage of a PEGylated polypeptide at a fixed temperature over time or during storage at variable temperatures. For example, PEGylation may be maintained during storage at 4° C., 15° C., 20° C., 25° C., 30° C., or 37° C. Alternatively, PEGylation may be maintained, for example, during storage at 4° C. for 2 weeks followed by storage at 25° C. for 1 week. In any case, the level of dePEGylation should be determined relative the initial level of PEGylation of the polypeptide.
- In certain embodiments, the methods described herein may involve first determining whether a PEGylated polypeptide is subject to dePEGylation at an undesirable level when stored at pH≧6.0. For example, the methods may comprise determining the level of dePEGylation of a PEGylated polypeptide during storage at pH≧6.0. If the level of dePEGylation is greater than 1%, 2%, 5%, 10% or 15%, the PEGylated polypeptide is reformulated in a solution having a pH≦6.0. Similarly, the methods may involve monitoring the PEGylation level of a PEGylated polypeptide formulated in a solution having a pH≧6.0 for a period of time. If more than 1%, 2%, 5%, 10% or 15% of the polypeptide is dePEGylated over a period of 2 weeks, 4 weeks, 3 months or 6 months, then the polypeptide may be reformulated in a solution having a pH≦6.0.
- In one embodiment, dePEGylation may be inhibited by a method comprising the steps of: (a) measuring PEGylation of the PEGylated polypeptides at an initial reference time point; (b) comparing PEGylation of the PEGylated polypeptides after an interval; (c) reducing pH of the solution to a value between pH 2.0 and pH 6.0; and (d) comparing PEGylation of the PEGylated polypeptides after an interval, wherein a decrease in dePEGylation of the PEGylated polypeptides after step (c) indicates inhibition of dePEGylation. In another embodiment, a method for inhibiting dePEGylation when storing PEGylated polypeptides may comprise: (a) storing the PEGylated polypeptides in a solution; (b) monitoring the PEGylation of the PEGylated polypeptides; and (c) lowering the pH of the solution to a value in between pH 2.0 and pH 6.0, wherein the pH is a value sufficient to inhibit dePEGylation.
- The methods and formulations described herein may be applied to any PEGylated polypeptide. The methods described herein are particularly suited to maintaining PEGylation of polypeptides that are susceptible to dePEGylation when stored in solutions having a pH≧6.0. In exemplary embodiments, the PEGylated polypeptides are therapeutic proteins, such as, for example, interferon alpha, adenosine deaminase, L-asparaginase, granulocyte colony-stimulating factor and antibodies, such as, for example, anti-tumor necrosis factor alpha antibodies. A PEGylated protein may be a protein binding specifically to a target, such as an antibody or an antigen binding fragment thereof and may be any of the following: a Fab, a F(ab′)2, an Fv, a single chain Fv fragment, a single domain antibody or a variant thereof (e.g., a heavy or light chain variable domain monomer or dimer, e.g., VH, VHH); a single chain Fc fragment, a diabody (dAb), a camelid antibody; one, two, or all three complementarity determining regions (CDRs) grafted onto a repertoire of VH or VL domains, or other scaffolds, an Affibody molecule (e.g., an Affibody protein Z scaffold or other molecules as described, e.g., in Lee et al., Clin. Cancer Res., 14(12):3840-3849 (2008); Ahlgren et al., Nucl. Med., 50:781-789 (2009)), lipocalin, ankyrin repeats, LDL receptor domain, RNA aptamer, PDZ domain, a multispecific (e.g., bivalent or bispecific) antibody or fragment thereof, a human antibody or antigen binding fragment thereof, a humanized antibody or antigen binding fragment thereof, a chimeric antibody or antigen binding fragment thereof, a camelid antibody or antigen binding fragment thereof, a shark antibody or antigen binding fragment thereof, or an in vitro generated antibody or antigen binding fragment thereof.
- In an exemplary embodiment, the PEGylated polypeptide is a fibronectin based scaffold protein (FBSP) as described further below. Exemplary FBSP include, for example, monovalent FBSP that bind to, for example, PCSK9 (FBSP-P) or VEGFR2 (FBSP-V), or multivalent FBSP, including, for example, bivalent FBSP that bind to VEGFR2 and IGF-1R (FBSP-VI).
- In some embodiments, the methods disclosed herein may be used to maintain PEGylation of fibronectin based scaffold proteins. This family of proteins is capable of evolving to bind any compound of interest. These proteins generally make use of a scaffold derived from a fibronectin type III (Fn3) or Fn3-like domain and function in a manner characteristic of natural or engineered antibodies (that is, polyclonal, monoclonal, or single-chain antibodies) and, in addition, possess structural advantages. Specifically, the structure of these antibody mimics has been designed for optimal folding, stability, and solubility, even under conditions that normally lead to the loss of structure and function in antibodies. An example of fibronectin-based scaffold proteins are ADNECTINS™ (Adnexus, a wholly owned subsidiary of Bristol-Myers Squibb). Fibronectin-based scaffold proteins and ADNECTINS™ may be monovalent or multivalent.
- An Fn3 domain is small, monomeric, soluble, and stable. It lacks disulfide bonds and, therefore, is stable under reducing conditions. The overall structure of Fn3 resembles the immunoglobulin fold. Fn3 domains comprise, in order from N-terminus to C-terminus, a beta or beta-like strand, A; a loop, AB; a beta or beta-like strand, B; a loop, BC; a beta or beta-like strand, C; a loop, CD; a beta or beta-like strand, D; a loop, DE; a beta or beta-like strand, E; a loop, EF; a beta or beta-like strand, F; a loop, FG; and a beta or beta-like strand, G. The seven antiparallel β-strands are arranged as two beta sheets that form a stable core, while creating two “faces” composed of the loops that connect the beta or beta-like strands. Loops AB, CD, and EF are located at one face and loops BC, DE, and FG are located on the opposing face. Any or all of loops AB, BC, CD, DE, EF and FG may participate in ligand binding. There are at least 15 different modules of Fn3, and while the sequence homology between the modules is low, they all share a high similarity in tertiary structure.
- The amino acid sequence of the naturally occurring human tenth fibronectin type III domain, i.e., the tenth module of human Fn3 (10Fn3), is set forth in SEQ ID NO: 1:
-
(SEQ ID NO: 1) VSDVPRDLEVVAATPTSLLISWDAPAVTVRYYRITYGETGGNSPVQEFTV PGSKST ATISGLKPGVDYTITVYAVTGRGDSPASSKPISINYRT (the AB, CD and EF loops are underlined. and the BC, FG, and DE loons are emphasized in bold). - In SEQ ID NO: 1, the AB loop corresponds to residues 15-16, the BC loop corresponds to residues 21-30, the CD loop corresponds to residues 39-45, the DE loop corresponds to residues 51-56, the EF loop corresponds to residues 60-66, and the FG loop corresponds to residues 76-87. (Xu et al., Chemistry & Biology, 9:933-942 (2002)). The BC, DE and FG loops align along one face of the molecule and the AB, CD and EF loops align along the opposite face of the molecule. In SEQ ID NO: 1, beta strand A corresponds to residues 9-14, beta strand B corresponds to residues 17-20, beta strand C corresponds to residues 31-38, beta strand D corresponds to residues 46-50, beta strand E corresponds to residues 57-59, beta strand F corresponds to residues 67-75, and beta strand G corresponds to residues 88-94. The strands are connected to each other through the corresponding loop, e.g., strands A and B are connected via loop AB in the formation strand A, loop AB, strand B, etc. The first 8 amino acids of SEQ ID NO:1 (italicized above) may be deleted while still retaining binding activity of the molecule. Residues involved in forming the hydrophobic core (the “core amino acid residues”) include the amino acids corresponding to the following amino acids of SEQ ID NO: 1: L8, V10, A13, L18, 120, W22, Y32, 134, Y36, F48, V50, A57, 159, L62, Y68, 170, V72, A74, 188, 190 and Y92, wherein the core amino acid residues are represented by the single letter amino acid code followed by the position at which they are located within SEQ ID NO: 1. See e.g., Dickinson et al., J. Mol. Biol., 236:1079-1092 (1994).
- 10Fn3 are structurally analogous to antibodies, specifically the variable region of an antibody. While 10Fn3 domains may be described as “antibody mimics” or “antibody-like proteins”, they do offer a number of advantages over conventional antibodies. In particular, they exhibit better folding and thermostability properties as compared to antibodies, and they lack disulphide bonds, which are known to impede or prevent proper folding under certain conditions.
- The BC, DE, and FG loops of 10Fn3 are analogous to the complementary determining regions (CDRs) from immunoglobulins. Alteration of the amino acid sequence in these loop regions changes the binding specificity of 10Fn3. 10Fn3 domains with modifications in the AB, CD and EF loops may also be made in order to produce a molecule that binds to a desired target. The protein sequences outside of the loops are analogous to the framework regions from immunoglobulins and play a role in the structural conformation of the 10Fn3. Alterations in the framework-like regions of 10Fn3 are permissible to the extent that the structural conformation is not so altered as to disrupt ligand binding. Methods for generating 10Fn3 ligand specific binders have been described in PCT Publication Nos. WO 00/034787, WO 01/64942, and WO 02/032925, disclosing high affinity TNFα binders, PCT Publication Nos. WO 2005/56764 and WO 2008/097497, disclosing high affinity VEGFR2 binders, and PCT Publication No. WO 2008/066752, disclosing high affinity IGFIR binders. Additional references discussing 10Fn3 binders (which may benefit from the methods described herein) and methods of selecting binders include PCT Publication Nos. WO 98/056915, WO 02/081497, WO 2008/031098, U.S. Publication No. 2003/186385, PCT Publication Nos. WO 2009/102421, WO 2009/142773, WO2010/060095, U.S. Pat. Nos. 6,818,418, 6,673,901, 7,115,396, PCT Publication Nos. WO 2010/0273261, WO 2011/103105, WO 2011/130354, WO 2011/140086, WO 2011/150133, WO 2010/051274, WO 2010/051310, WO 2009/086116, WO 2009/086116, WO 2010/093627, WO 2011/137319, WO 2012/016245, WO 98/056915, WO 02/081497, WO 2008/031098, U.S. Publication No. 2003/186385, PCT Publication Nos. WO 2011/130324, WO 2011/130328, WO 2009/083804, WO 2009/133208, WO 2010/093627, WO 2011/051333, WO 2011/051466, and WO 2011/092233.
- As described above, amino acid residues corresponding to residues 21-30, 51-56, and 76-87 of SEQ ID NO: 1 define the BC, DE and FG loops, respectively. However, it should be understood that not every residue within the loop region needs to be modified in order to achieve a 10Fn3 binder having strong affinity for a desired target. For example, in many cases, only residues corresponding to amino acids 23-30 of the BC loop and 52-55 of the DE loop are modified and result in high affinity 10Fn3 binders. Accordingly, in certain embodiments, the BC loop may be defined by amino acids corresponding to residues 23-30 of SEQ ID NO: 1, and the DE loop may be defined by amino acids corresponding to residues 52-55 of SEQ ID NO: 1. Additionally, insertions and deletions in the loop regions may also be made while still producing high affinity 10Fn3 binders.
- Accordingly, in some embodiments, one or more loops selected from BC, DE, and FG may be extended or shortened in length relative to the corresponding loop in wild-type human 10Fn3. In some embodiments, the length of the loop may be extended by from 2-25 amino acids. In some embodiments, the length of the loop may be decreased by 1-11 amino acids. In particular, the FG loop of 10Fn3 is 12 residues long, whereas the corresponding loop in antibody heavy chains ranges from 4-28 residues. To optimize antigen binding, therefore, the length of the FG loop of 10Fn3 may be altered in length as well as in sequence to cover the CDR3 range of 4-28 residues to obtain the greatest possible flexibility and affinity in antigen binding. In some embodiments, the integrin-binding motif “arginine-glycine-aspartic acid” (RGD), located at residues 79-81 of SEQ ID NO: 1, may be modified in order to disrupt integrin binding. For example, the RGD sequence may be replaced with SGE.
- The non-ligand binding sequences of 10Fn3, i.e., the “10Fn3 scaffold”, may be altered provided that the 10Fn3 retains ligand binding function and/or structural stability. In some embodiments, one or more of
Asp 7, Glu 9, and Asp 23 are replaced by another amino acid, such as, for example, a non-negatively charged amino acid residue (e.g., Asn, Lys, etc.). These mutations have been reported to have the effect of promoting greater stability of the mutant 10Fn3 at neutral pH as compared to the wild-type form (See, PCT Publication No. WO 02/04523). A variety of additional alterations in the 10Fn3 scaffold that are either beneficial or neutral have been disclosed. See, for example, Batori et al., Protein Eng., 15(12):1015-1020 (2002); Koide et al., Biochemistry, 40(34):10326-10333 (2001). - Residues involved in forming the hydrophobic core (the “core amino acid residues”) in SEQ ID NO: 1 include the amino acids corresponding to the following amino acids of SEQ ID NO: 1: L8, V10, A13, L18, 120, W22, Y32, 134, Y36, F48, V50, A57, 159, L62, Y68, 170, V72, A74, 188, 190 and Y92, wherein the core amino acid residues are represented by the single letter amino acid code followed by the position at which they are located within SEQ ID NO: 1. See e.g., Dickinson et al., J. Mol. Biol., 236:1079-1092 (1994). In some embodiments, the hydrophobic core amino acids are not modified relative to the wild-type sequence. In other embodiments, the following hydrophobic amino acids may be mutated: W22 and/or L62.
- The 10Fn3 scaffold may be modified by one or more conservative substitutions. As many as 5%, 10%, 20% or even 30% or more of the amino acids in the 10Fn3 scaffold may be altered by a conservative substitution without substantially altering the affinity of the 10Fn3 for a ligand. In certain embodiments, the scaffold may comprise anywhere from 0-15, 0-10, 0-8, 0-6, 0-5, 0-4, 0-3, 1-15, 1-10, 1-8, 1-6, 1-5, 1-4, 1-3, 2-15, 2-10, 2-8, 2-6, 2-5, 2-4, 5-15, or 5-10 conservative amino acid substitutions. In certain embodiments, the substitutions in the scaffold do not include substitutions of the hydrophobic core amino acid residues. Preferably, the scaffold modification reduces the binding affinity of the 10Fn3 binder for a ligand by less than 100-fold, 50-fold, 25-fold, 10-fold, 5-fold, or 2-fold. It may be that such changes will alter the immunogenicity of the 10Fn3 in vivo, and where the immunogenicity is decreased, such changes will be desirable. As used herein, “conservative substitutions” refers to replacement of one amino acid with another amino acid that is physically or functionally similar to the amino acid being replaced. That is, a conservative substitution and its reference residue have similar size, shape, electric charge, chemical properties including the ability to form covalent or hydrogen bonds, or the like. Preferred conservative substitutions are those fulfilling the criteria defined for an accepted point mutation in Dayhoff et al., Atlas of Protein Sequence and Structure, 5:345-352 (1978 & Supp.). Examples of conservative substitutions are substitutions within the following groups: (a) valine, glycine; (b) glycine, alanine; (c) valine, isoleucine, leucine; (d) aspartic acid, glutamic acid; (e) asparagine, glutamine; (f) serine, threonine; (g) lysine, arginine, methionine; and (h) phenylalanine, tyrosine.
- In some embodiments, a fibronectin based scaffold protein comprises a 10Fn3 domain having at least 40%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, or 90% identity to the human 10Fn3 domain having the amino acid sequence of SEQ ID NO: 1. Much of the variability will generally occur in one or more of the loops. Each of the beta or beta-like strands of a 10Fn3 domain in a fibronectin based scaffold protein may comprise, consist essentially of, or consist of an amino acid sequence that is at least 80%, 85%, 90%, 95% or 100% identical to the sequence of a corresponding beta or beta-like strand of SEQ ID NO: 1, provided that such variation does not disrupt the stability of the polypeptide in physiological conditions. In exemplary embodiments, the 10Fn3 domain binds to a desired target with a KD of less than 500 nM, 100 nM, 10 nM, 1 nM, 500 pM, 100 pM or less. In exemplary embodiments, the fibronectin based scaffold protein binds specifically to a target that is not bound by a wild-type 10Fn3 domain, particularly the wild-type human 10Fn3 domain.
- In some embodiments, the fibronectin based scaffold protein comprises a 10Fn3 domain having an amino acid sequence at least 80, 85, 90, 95, 98, or 100% identical to the non-loop regions of SEQ ID NO: 1, wherein at least one loop selected from BC, DE, and FG is altered. In some embodiments, the altered BC loop has up to 10 amino acid substitutions, up to 4 amino acid deletions, up to 10 amino acid insertions, or a combination thereof. In some embodiments, the altered DE loop has up to 6 amino acid substitutions, up to 4 amino acid deletions, up to 13 amino acid insertions, or a combination thereof. In some embodiments, the FG loop has up to 12 amino acid substitutions, up to 11 amino acid deletions, up to 25 amino acid insertions, or a combination thereof.
- In some embodiments, the disclosure provides polypeptides comprising a 10Fn3 domain, wherein the 10Fn3 domain comprises a loop, AB; a loop, BC; a loop, CD; a loop, DE; a loop, EF; and a loop, FG; and has at least one loop selected from loop BC, DE, and FG with an altered amino acid sequence relative to the sequence of the corresponding loop of the human 10Fn3 domain. In some embodiments, the BC and FG loops are altered. In some embodiments, the BC, DE, and FG loops are altered, i.e., the 10Fn3 domain comprises non-naturally occurring loops. By “altered” is meant one or more amino acid sequence alterations relative to a template sequence (i.e., the corresponding human fibronectin domain) and includes amino acid additions, deletions, and substitutions. Altering an amino acid sequence may be accomplished through intentional, blind, or spontaneous sequence variation, generally of a nucleic acid coding sequence, and may occur by any technique, for example, PCR, error-prone PCR, or chemical DNA synthesis.
- In certain embodiments, antibody-like proteins based on the 10Fn3 scaffold can be defined generally by the following core amino acid sequence:
-
(SEQ ID NO: 2) EVVAAT(X)aSLLI(X)xYYRITYGE(X)bQEFTV(X)yATI(X)cDYTITVYAV(X)zISINYR T - In SEQ ID NO: 2, the AB loop is represented by Xa, the CD loop is represented by Xb, the EF loop is represented by Xc, the BC loop is represented by Xx, the DE loop is represented by Xy, and the FG loop is represented by Xz. X represents any amino acid and the subscript following the X represents an integer of the number of amino acids. In particular, a may be anywhere from 1-15, 2-15, 1-10, 2-10, 1-8, 2-8, 1-5, 2-5, 1-4, 2-4, 1-3, 2-3, or 1-2 amino acids; and b, c, x, y and z may each independently be anywhere from 2-20, 2-15, 2-10, 2-8, 5-20, 5-15, 5-10, 5-8, 6-20, 6-15, 6-10, 6-8, 2-7, 5-7, or 6-7 amino acids. In preferred embodiments, a is 2 amino acids, b is 7 amino acids, c is 7 amino acids, x is 9 amino acids, y is 6 amino acids, and z is 12 amino acids. The sequences of the beta strands may have anywhere from 0 to 10, from 0 to 8, from 0 to 6, from 0 to 5, from 0 to 4, from 0 to 3, from 0 to 2, or from 0 to 1 substitutions, deletions or additions across all 7 scaffold regions relative to the corresponding amino acids shown in SEQ ID NO: 1. In an exemplary embodiment, the sequences of the beta strands may have anywhere from 0 to 10, from 0 to 8, from 0 to 6, from 0 to 5, from 0 to 4, from 0 to 3, from 0 to 2, or from 0 to 1 conservative substitutions across all 7 scaffold regions relative to the corresponding amino acids shown in SEQ ID NO: 1. In certain embodiments, the hydrophobic core amino acid residues are fixed and any substitutions, conservative substitutions, deletions or additions occur at residues other than the core amino acid residues. In exemplary embodiments, the BC, DE, and FG loops as represented by (X)x, (X)y, and (X)z, respectively, are replaced with polypeptides comprising BC, DE and FG loop sequences that bind to specific targets.
- In certain embodiments, Antibody-like proteins based on the 10Fn3 scaffold can be defined generally by the sequence:
-
(SEQ ID NO: 3) EVVAATPTSLLI(X)xYYRITYGETGGNSPVQEFTV(X)yATISGLKPGVDYTITVYAV (X)zISINYRT - In SEQ ID NO: 3, the BC loop is represented by Xx, the DE loop is represented by Xy, and the FG loop is represented by Xz. X represents any amino acid and the subscript following the X represents an integer of the number of amino acids. In particular, x, y and z may each independently be anywhere from 2-20, 2-15, 2-10, 2-8, 5-20, 5-15, 5-10, 5-8, 6-20, 6-15, 6-10, 6-8, 2-7, 5-7, or 6-7 amino acids. In preferred embodiments, x is 9 amino acids, y is 6 amino acids, and z is 12 amino acids. The sequences of the beta strands may have anywhere from 0 to 10, from 0 to 8, from 0 to 6, from 0 to 5, from 0 to 4, from 0 to 3, from 0 to 2, or from 0 to 1 substitutions, deletions or additions across all 7 scaffold regions relative to the corresponding amino acids shown in SEQ ID NO: 1. In an exemplary embodiment, the sequences of the beta strands may have anywhere from 0 to 10, from 0 to 8, from 0 to 6, from 0 to 5, from 0 to 4, from 0 to 3, from 0 to 2, or from 0 to 1 conservative substitutions across all 7 scaffold regions relative to the corresponding amino acids shown in SEQ ID NO: 1. In certain embodiments, the core amino acid residues are fixed and any substitutions, conservative substitutions, deletions or additions occur at residues other than the core amino acid residues. In exemplary embodiments, the BC, DE, and FG loops as represented by (X)x, (X)y, and (X)z, respectively, are replaced with polypeptides comprising BC, DE and FG loop sequences that bind to specific targets.
- A 10Fn3 domain as described herein may optionally contain a modified N- and/or C-terminal sequence. For example, with reference to SEQ ID NO: 2 or 3, the 10Fn3 domain may comprise an N-terminal extension and/or a C-terminal tail as described further below.
- In certain embodiments, the 10Fn3 domain as shown in SEQ ID NO: 2 or 3 may optionally comprise an N-terminal extension of from 1-20, 1-15, 1-10, 1-8, 1-5, 1-4, 1-3, 1-2, or 1 amino acids in length. Exemplary N-terminal extensions include (represented by the single letter amino acid code) M, MG, G, MGVSDVPRDL (SEQ ID NO: 17), VSDVPRDL (SEQ ID NO: 18), and GVSDVPRDL (SEQ ID NO: 19), or N-terminal truncations of any one of SEQ ID NOs: 17, 18 or 19. Other suitable N-terminal extensions include, for example, XnSDVPRDL (SEQ ID NO: 20), XnDVPRDL (SEQ ID NO: 21), XnVPRDL (SEQ ID NO: 22), XnPRDL (SEQ ID NO: 23), XnRDL (SEQ ID NO: 24), XnDL (SEQ ID NO: 25), or XnL, wherein n=0, 1 or 2 amino acids, wherein when n=1, X is Met or Gly, and when n=2, X is Met-Gly. When a Met-Gly sequence is added to the N-terminus of a 10Fn3 domain, the M will usually be cleaved off, leaving a G at the N-terminus.
- In certain embodiments, the 10Fn3 domain as shown in SEQ ID NO: 2 or 3 may optionally comprise a C-terminal tail of from 1-20, 1-15, 1-10, 1-8, 1-5, or 1-4 amino acids in length. Specific examples of tail sequences include, for example, polypeptides comprising, consisting essentially of, or consisting of, EIEK (SEQ ID NO: 5), EGSGC (SEQ ID NO: 10), EIEKPCQ (SEQ ID NO: 11), EIEKPSQ (SEQ ID NO: 26), EIEKP (SEQ ID NO: 27), EIEKPS (SEQ ID NO: 28), EIEKPC (SEQ ID NO: 12), EIDKPSQ (SEQ ID NO: 14), or EIDKPSQLE (SEQ ID NO: 16). In certain embodiments, the 10Fn3 domain comprises a C-terminal tail comprising a sequence X(ED)n, wherein n is an integer from 2-10, 2-8, 2-5, 3-10, 3-8, 3-7, 3-5, 4-7, or wherein n is 2, 3, 4, 5, 6, 7, 8, 9 or 10, and X is optional, and when present is an E, I or EI. Such ED repeat tails may enhance solubility and/or reduce aggregation of the 10Fn3 domain. In exemplary embodiments, the C-terminal tail comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 11. In preferred embodiments, the C-terminal sequences lack DK sequences. In exemplary embodiments, the C-terminal tail comprises a residue that facilitates modification by PEG, i.e., a lysine or cysteine residue. In preferred embodiments, the C-terminal tail lacks a DK sequence and comprises a cysteine residue.
- In certain embodiments, the fibronectin based scaffold proteins comprise a 10Fn3 domain having both an N-terminal extension and a C-terminal tail.
- In certain embodiments, the fibronectin based scaffold protein is a multivalent protein that comprises two or more 10Fn3 domains as described herein. For example, a multivalent fibronectin based scaffold protein may comprise 2, 3 or more 10Fn3 domains that are covalently associated. In exemplary embodiments, the fibronectin based scaffold protein is a bispecific or dimeric protein comprising two 10Fn3 domains. In certain embodiments, a multivalent fibronectin based protein scaffold comprises a first 10Fn3 domain that binds to a first target molecule and a second 10Fn3 domain that binds to a second target molecule. The first and second target molecules may be the same or different target molecules. When the first and second target molecules are the same, the 10Fn3 domains, i.e., the binding loops, may be the same or different. Furthermore, when the first and second 10Fn3 domains bind to the same target, they may bind to the same or different epitopes on the target.
- In exemplary embodiments, each 10Fn3 domain of a multivalent fibronectin based protein scaffold binds to a desired target with a KD of less than 500 nM, 100 nM, 10 nM, 1 nM, 500 pM, 100 pM or less. In exemplary embodiments, each 10Fn3 domain of a multivalent fibronectin based protein scaffold binds specifically to a target that is not bound by a wild-type 10Fn3 domain, particularly the wild-type human 10Fn3 domain.
- The 10Fn3 domains in a multivalent fibronectin based scaffold protein may be connected by a polypeptide linker. Exemplary polypeptide linkers include polypeptides having from 1-20, 1-15, 1-10, 1-8, 1-5, 1-4, 1-3, or 1-2 amino acids. Suitable linkers for joining the 10Fn3 domains are those which allow the separate domains to fold independently of each other forming a three dimensional structure that permits high affinity binding to a target molecule. The application provides that suitable linkers that meet these requirements comprise glycine-serine based linkers, glycine-proline based linkers, proline-alanine based linkers as well as the linker SEQ ID NO: 31. The Examples described in WO 2009/142773 demonstrate that Fn3 domains joined via these linkers retain their target binding function. In some embodiments, the linker is a glycine-serine based linker. These linkers comprise glycine and serine residues and may be between 8 and 50, 10 and 30, and 10 and 20 amino acids in length. Examples of such linkers include SEQ ID NOs: 32-36. In some embodiments, the linker is a glycine-proline based linker. These linkers comprise glycine and proline residues and may be between 3 and 30, 10 and 30, and 3 and 20 amino acids in length. Examples of such linkers include SEQ ID NOs: 37, 38 and 39. In some embodiments, the linker is a proline-alanine based linker. These linkers comprise proline and alanine residues and may be between 3 and 30, 10 and 30, 3 and 20 and 6 and 18 amino acids in length. Examples of such linkers include SEQ ID NOs: 40, 41 and 42. It is contemplated, that the optimal linker length and amino acid composition may be determined by routine experimentation based on the teachings provided herein. In exemplary embodiments, the linker does not contain any DK sequences. In certain embodiments, the linker may be a C-terminal tail polypeptide as described herein, an N-terminal extension polypeptide as described herein, a linker polypeptide as described herein, or any combination thereof.
- In the case of multivalent fibronectin based scaffold proteins, preferably none of the 10Fn3 domains comprise a C-terminal tail containing a DK sequence. In exemplary embodiments, a multivalent fibronectin based scaffold protein comprises two or more 10Fn3 domains, wherein each domain comprises a C-terminal tail that does not contain a DK sequence. In certain embodiments, a multivalent fibronectin based scaffold protein comprises two or more 10Fn3 domains, wherein each domain comprises a C-terminal tail that does not contain a DK sequence and at least one of the domains comprises a residue suitable for addition of a PEG moiety, such as a lysine or cysteine residue.
- PEG is a well-known, water soluble polymer that may be obtained commercially or prepared by ring-opening polymerization of ethylene glycol according to methods well known in the art (Sandler et al., Polymer Synthesis, Vol. 3, pp. 138-161, Academic Press, NY). The term “PEG” is used broadly to encompass any polyethylene glycol molecule, without regard to size or to modification at an end of the PEG, and can be represented by the formula:
- X—O(CH2CH2O)n-1CH2CH2OH (1), where n is 20 to 2300 and X is H or a terminal modification, e.g., a C1-4 alkyl. In one embodiment, the PEG of the invention terminates on one end with hydroxy or methoxy, i.e., X is H or CH3 (“methoxy PEG”). A PEG can contain further chemical groups which are necessary for binding reactions; which results from the chemical synthesis of the molecule; or which is a spacer for optimal distance of parts of the molecule. In addition, such a PEG can consist of one or more PEG side-chains which are linked together. PEGs with more than one PEG chain are called multiarmed or branched PEGs. Branched PEGs can be prepared, for example, by the addition of polyethylene oxide to various polyols, including glycerol, pentaerythriol, and sorbitol. For example, a four-armed branched PEG can be prepared from pentaerythriol and ethylene oxide. Branched PEG are described in, for example, European Published Application No. 473084A and U.S. Pat. No. 5,932,462. One form of PEGs includes two PEG side-chains (PEG2) linked via the primary amino groups of a lysine (Monfardini, C. et al., Bioconjugate Chem., 6:62-69 (1995)).
- PEG conjugation to peptides or proteins generally involves the activation of PEG and coupling of the activated PEG-intermediates directly to target proteins/peptides or to a linker, which is subsequently activated and coupled to target proteins/peptides (see Abuchowski, A. et al., J. Biol. Chem., 252:3571 (1977) and J. Biol. Chem., 252:3582 (1977), Zalipsky et al. and Harris et al., in: Poly(ethylene glycol) Chemistry: Biotechnical and Biomedical Applications, Chapters 21 and 22, Harris, J. M., ed., Plenum Press, NY (1992)). It is noted that a polypeptide containing a PEG molecule is also known as a conjugated or PEGylated protein, whereas the protein lacking an attached PEG molecule can be referred to as unconjugated or free.
- The size of PEG utilized will depend on several factors including the intended use of the polypeptide. Larger PEGs are preferred to increase half life in the body, blood, non-blood extracellular fluids or tissues. For in vivo cellular activity, PEGs of the range of about 10 to 60 kDa are preferred, as well as PEGs less than about 100 kDa and more preferably less than about 60 kDa, though sizes greater than about 100 kDa can be used as well. For in vivo imaging applications, smaller PEGs, generally less than about 20 kDa, may be used that do not increase half life as much as larger PEGs so as to permit quicker distribution and less half life. A variety of molecular mass forms of PEG can be selected, e.g., from about 1,000 Daltons (Da) to 100,000 Da (n is 20 to 2300), for conjugating to polypeptides of the invention. The number of repeating units “n” in the PEG is approximated for the molecular mass described in Daltons. It is preferred that the combined molecular mass of PEG on an activated linker is suitable for pharmaceutical use. Thus, in one embodiment, the molecular mass of the PEG molecules does not exceed 100,000 Da. For example, if three PEG molecules are attached to a linker, where each PEG molecule has the same molecular mass of 12,000 Da (each n is about 270), then the total molecular mass of PEG on the linker is about 36,000 Da (total n is about 820). The molecular masses of the PEG attached to the linker can also be different, e.g., of three molecules on a linker two PEG molecules can be 5,000 Da each (each n is about 110) and one PEG molecule can be 12,000 Da (n is about 270). In some embodiments, one PEG moiety is conjugated to the polypeptide. In some embodiments, the PEG moiety is about 30, 40, 50, 60, 70, 80, or 90 KDa.
- In some embodiments, PEGylated polypeptides contain one, two or more PEG moieties. In one embodiment, the PEG moiety(ies) are bound to an amino acid residue which is on the surface of the protein and/or away from the surface that contacts the target ligand. In one embodiment, the combined or total molecular mass of PEG in a PEGylated polypeptide is from about 3,000 Da to 60,000 Da, from about 10,000 Da to 36,000 Da, or from about 35,000 Da to 45,000 Da, or about 40,000 Da. In a one embodiment, the PEG in a PEGylated polypeptide is a substantially linear, straight-chain PEG.
- One skilled in the art can select a suitable molecular mass for PEG, e.g., based on how the pegylated polypeptide will be used therapeutically, the desired dosage, circulation time, resistance to proteolysis, immunogenicity, and other considerations. For a discussion of PEG and its use to enhance the properties of proteins, see Katre, N. V., Advanced Drug Delivery Reviews, 10:91-114 (1993).
- In some embodiments, a polypeptide is covalently linked to one poly(ethylene glycol) group of the formula: —CO—(CH2)x—(OCH2CH2)—m—OR, with the —CO (i.e., carbonyl) of the poly(ethylene glycol) group forming an amide bond with one of the amino groups of the polypeptide; R being lower alkyl; x being 2 or 3; m being from about 450 to about 950; and n and m being chosen so that the molecular weight of the conjugate minus the polypeptide is from about 10 to 40 kDa. In one embodiment, a polypeptide's ε-amino group of a lysine is the available (free) amino group.
- In one specific embodiment, carbonate esters of PEG are used to form the PEG-polypeptide conjugates. N,N′-disuccinimidylcarbonate (DSC) may be used in the reaction with PEG to form active mixed PEG-succinimidyl carbonate that may be subsequently reacted with a nucleophilic group of a linker or an amino group of a polypeptide (see U.S. Pat. Nos. 5,281,698 and 5,932,462). In a similar type of reaction, 1,1′-(dibenzotriazolyl)carbonate and di-(2-pyridyl)carbonate may be reacted with PEG to form PEG-benzotriazolyl and PEG-pyridyl mixed carbonate (U.S. Pat. No. 5,382,657), respectively.
- PEGylation of a polypeptide can be performed according to the methods of the state of the art, for example by reaction of the polypeptide with electrophilically active PEGs (supplier: Shearwater Corp., USA, www.shearwatercorp.com). Preferred PEG reagents of the present invention are, e.g., N-hydroxysuccinimidyl propionates (PEG-SPA), butanoates (PEG-SBA), PEG-succinimidyl propionate or branched N-hydroxysuccinimides such as mPEG2-NHS (Monfardini, C., et al., Bioconjugate Chem., 6:62-69 (1995)). Such methods may used to pegylate at an ε-amino group of a polypeptide lysine or the N-terminal amino group of the polypeptide.
- In another embodiment, PEG molecules may be coupled to sulfhydryl groups on a polypeptide (Sartore, L. et al., Appl. Biochem. Biotechnol., 27:45 (1991); Morpurgo et al., Bioconjugate Chem., 7:363-368 (1996); Goodson et al., Bio/Technology, 8:343 (1990); U.S. Pat. No. 5,766,897). U.S. Pat. Nos. 6,610,281 and 5,766,897 describe exemplary reactive PEG species that may be coupled to sulfhydryl groups.
- In some embodiments, the pegylated polypeptide is produced by site-directed PEGylation, particularly by conjugation of PEG to a cysteine moiety at the N- or C-terminus. In some embodiments, the polypeptide is an Fn3 domain covalently bound to a PEG moiety, wherein at least one of the loops of said Fn3 domain participates in binding to a target. The PEG moiety may be attached to the Fn3 polypeptide by site directed PEGylation, such as by attachment to a Cys residue, where the Cys residue may be positioned at the N-terminus of the Fn3 polypeptide or between the N-terminus and the most N-terminal beta or beta-like strand or at the C-terminus of the Fn3 polypeptide or between the C-terminus and the most C-terminal beta or beta-like strand. A Cys residue may be situated at other positions as well, particularly any of the loops that do not participate in target binding. A PEG moiety may also be attached by other chemistry, including by conjugation to amines.
- In some embodiments where PEG molecules are conjugated to cysteine residues on a polypeptide, the cysteine residues are native to the polypeptide, whereas in other embodiments, one or more cysteine residues are engineered into the polypeptide. Mutations may be introduced into a polypeptide coding sequence to generate cysteine residues. This might be achieved, for example, by mutating one or more amino acid residues to cysteine. Preferred amino acids for mutating to a cysteine residue include serine, threonine, alanine and other hydrophilic residues. Preferably, the residue to be mutated to cysteine is a surface-exposed residue. Algorithms are well-known in the art for predicting surface accessibility of residues based on primary sequence or a protein. Alternatively, surface residues may be predicted by comparing the amino acid sequences of polypeptides, given that the crystal structure of the framework based on which polypeptides are designed and evolved has been solved (see Himanen et al., Nature, 414(6866):933-938 (Dec. 20-27, 2001)) and thus the surface-exposed residues identified. In one embodiment, cysteine residues are introduced into polypeptides at or near the N- and/or C-terminus, or within loop regions. PEGylation of cysteine residues may be carried out using, for example, PEG-maleimide, PEG-vinylsulfone, PEG-iodoacetamide, or PEG-orthopyridyl disulfide. In exemplary embodiments, polypeptides are PEGylated on a cysteine residue using a maleimide linker.
- In some embodiments, the pegylated polypeptide comprises a PEG molecule covalently attached to the alpha amino group of the N-terminal amino acid. Site specific N-terminal reductive amination is described in Pepinsky et al., J. Pharmacol. Exp. Ther., 297:1059 (2001), and U.S. Pat. No. 5,824,784. The use of a PEG-aldehyde for the reductive amination of a protein utilizing other available nucleophilic amino groups is described in U.S. Pat. No. 4,002,531, in Wieder et al., J. Biol. Chem., 254:12579 (1979), and in Chamow et al., Bioconjugate Chem., 5:133 (1994).
- In another embodiment, pegylated polypeptide comprises one or more PEG molecules covalently attached to a linker, which in turn is attached to the alpha amino group of the amino acid residue at the N-terminus of the polypeptide. Such an approach is disclosed in U.S. Publication No. 2002/0044921 and PCT Publication No. WO 94/01451.
- In one embodiment, a polypeptide is PEGylated at the C-terminus. In a specific embodiment, a protein is pegylated at the C-terminus by the introduction of C-terminal azido-methionine and the subsequent conjugation of a methyl-PEG-triarylphosphine compound via the Staudinger reaction. This C-terminal conjugation method is described in Cazalis et al., “C-Terminal Site-Specific PEGylation of a Truncated Thrombomodulin Mutant with Retention of Full Bioactivity”, Bioconjugate Chem., 15(5):1005-1009 (2004).
- In exemplary embodiments, a fibronectin based scaffold protein is pegylated in a C-terminal tail region as described further herein. Exemplary C-terminal tails include, for example, a polypeptide having any one of SEQ ID NOs: 10, 11, or 12.
- In some embodiments, a branched PEG moiety may be conjugated to a protein via a lone cysteine residue on the protein. The chemistry of this conjugation may be, for example, highly selective maleimide chemistry in which free electrons on the sulfhydryl group on the protein attach to the maleimide group on the PEG via Michael Addition (
FIG. 1 , where the protein is represented by R′ and PEG molecule is represented by R). Specifically, the maleimide moiety forms a thioether bond with a sulfhydryl group on the protein. The Michael Addition reaction may be performed at a pH between pH 5.0 and pH 5.5 inclusive, or between pH 6.0 and 8.0 inclusive. - Conventional separation and purification techniques known in the art can be used to purify PEGylated polypeptides, such as size exclusion (e.g., gel filtration) and ion exchange chromatography. Products may also be separated using SDS-PAGE. Products that may be separated include mono-, di-, tri-, poly- and un-pegylated polypeptides, as well as free PEG. The percentage of mono-PEG conjugates can be controlled by pooling broader fractions around the elution peak to increase the percentage of mono-PEG in the composition. About ninety percent mono-PEG conjugates represents a good balance of yield and activity. Compositions in which, for example, at least ninety-two percent or at least ninety-six percent of the conjugates are mono-PEG species may be desired.
- In certain embodiments, the pegylated polypeptides will preferably retain at least about 25%, 50%, 60%, 70%, 80%, 85%, 90%, 95% or 100% of the biological activity associated with the unmodified protein. In one embodiment, biological activity refers to its ability to bind to its target, as assessed by KD, kon or koff.
- The serum clearance rate of PEG-modified polypeptides may be decreased by about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or even 90%, relative to the clearance rate of the unmodified polypeptide. The PEG-modified polypeptide may have a half-life (t1/2) which is enhanced relative to the half-life of the unmodified protein. The half-life of the PEG-polypeptide may be enhanced by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 125%, 150%, 175%, 200%, 250%, 300%, 400% or 500%, or even by 1000% relative to the half-life of the unmodified polypeptide. In some embodiments, the protein half-life is determined in vitro, such as in a buffered saline solution or in serum. In other embodiments, the protein half-life is an in vivo half life, such as the half-life of the protein in the serum or other bodily fluid of an animal.
- In certain embodiments, a PEGylated polypeptide has a shelf-life of at least 6 months, 1 year, 2 years, 3 years, 4 years, 5 years or more when formulated at a pH between pH 2.0 and pH 6.0 (e.g., a pH between pH 3.0 and 5.0).
- The invention now being generally described will be more readily understood by reference to the following examples which are included merely for purposes of illustration of certain aspects and embodiments of the present invention, and are not intended to limit the invention in any way.
- An exemplary fibronectin-based scaffold protein is FBSP-P, which is a mono-ADNECTIN™ having high affinity binding to PCSK9. FBSP-P is conjugated to a 40 kDa branched PEG via a lone cysteine residue on the protein. During formulation development of FBSP-P, an initial pH range of 6.0 to 7.5 was examined since, at the time, a neutral pH was thought to be desirable for the subcutaneous administration of the product. An example of the RP-HPLC results can be seen in
FIG. 2 . Samples were run on a Polymer Labs PLRP-S column, 2.0*150 mm, with a column temperature of 40° C. and an H2O/ACN/TFA gradient. Dual detection was performed with UV and Evaporative Light Scattering (ELS), which measures a relative quantification of protein-related impurities by UV signal and quantifies free PEG species by ELS signal using a PEG calibration curve. - From the preliminary data of the pH screen, an increase in the level of free PEG and protein fragments was observed as a function of increasing pH. Characterization of the protein fragments was performed by LC-MS, which identified these species to be that of the intact, free (unPEGylated) FBSP-P ADNECTIN™ and its covalent dimer (
FIG. 3 and Table 1). - Unlike previous ADNECTIN™ molecules, FBSP-P showed no clipping along its protein backbone due to the substitution of the aspartic acid in the C-terminal tail region with a glutamic acid at the position corresponding to amino acid residue 97 of SEQ ID NO: 47 (i.e., a DK-construct). Although several other aspartic acid residues exist in the protein sequence, these did not lead to clipping and only the fragment peaks identified in
FIG. 3 and Table 1 were consistently observed during formulation development and stability. - With the fragmented species characterized, and no other clipped species observed, this was the first occasion where dePEGylation could be clearly identified in ADNECTINS™. Based on these preliminary data, a lower pH range of 4 to 6 was examined for dePEGylation, and the complete set of results covering the entire pH range of 4 to 7.5 can be seen in
FIG. 4 andFIG. 5 , where the mole % of free PEG detected is plotted as % increase since T=0. InFIGS. 4 and 5 , data have been normalized for more direct comparison since two different batches of FBSP-P drug substance were used in the experiments, with the earlier lot showing a higher initial level of free PEG and free ADNECTIN™. The negative values were likely a result of assay variability and the low level of free PEG in these samples. - From the data presented above, a clear pH dependency can be seen in the level of dePEGylation. In the lower pH formulations, some instances of decreased levels of free PEG can be seen, which was likely attributed to the very low levels of free PEG detected along with variability with the ELS detection. Since the balance of dePEGylation is the free (unPEGylated) ADNECTIN™, the pH effect on the formation of that species is also evaluated and this is presented in
FIG. 6 andFIG. 7 . - Increased levels of free PEG and free (unPEGylated) ADNECTIN™ correlate very well to each other, at two elevated temperatures, with both showing a pH dependency.
- Following the discovery of dePEGylation with certain formulations of FBSP-P, other ADNECTINS™ were examined to determine if they were subject to the same degradation. FBSP-V is an ADNECTIN™ that binds to VEGFR2 with high affinity and having the sequence of SEQ ID NO: 48. FBSP-V is conjugated to a 40 kDa branched PEG moiety via a lone cysteine residue at position 93 of SEQ ID NO: 48. DePEGylation of FBSP-V was evaluated using a set of formulations ranging from pH 4.5 to 6.5. Similar to FBSP-P, the free (unPEGylated) FBSP-Vfree ADNECTIN™ was evident in these samples and its relative level also increased as a function of increasing pH. The LC-MS results of the most degraded sample at pH 6.5 are shown in
FIG. 8 and Table 2. Relative quantification of these fragmented species can be seen in - Table 3.
- With FBSP-V containing a DK in the C-terminal tail region (i.e., the aspartic acid at position 90 of SEQ ID NO: 48), two additional clips were also observed which represented cleavage at the aspartic acid at position 90. As previously established with other ADNECTIN™ molecules, formulations at lower pH leads to higher level of DK cleavages. The data in
- Table 3 indicates this trend in regard to total pre-peaks; however, as the pH increases, the % of intact free ADNECTIN™ increases, which was the same trend as that observed in FBSP-P as described in Example 1.
- Analysis of the same FBSP-V stability samples by SDS-PAGE revealed similar information in a qualitative manner (
FIG. 9 ). For stressed samples at the lowest pH (pH 4.5, inlanes 5 and 6), a clipped species can be seen above the 6 kD MW marker, corresponding to the dominant clip (G2-D91, corresponding to residues 1-90 of SEQ ID NO: 48). The presence of sodium chloride in the sample showed a higher level of this clip as compared to the sample formulated without sodium chloride at the same pH. As the pH of the formulation increased, this clip decreased in intensity but another band at slightly higher molecular weight now appeared, corresponding in molecular weight to the free FBSP-Vfree ADNECTIN™ at just above 10 kD. Moreover, the new band (indicated with an arrow) appeared to increase in intensity as the formulation pH increased from 5.5 to 6.5. These observations are consistent with those described inFIG. 8 , Table 2 and - Table 3.
- Another exemplary fibronectin-based scaffold protein is FBSP-V/I, a multivalent polypeptide with high affinity to VEGFR2 and IGF-IR. FBSP-V/I comprises the amino acid sequence of SEQ ID NO: 9, and contains a single 40 kDa branched PEG conjugated to the cysteine at position 203 of SEQ ID NO:9.
- Characterization of a stressed FBSP-V/I sample is shown in
FIG. 10 . The results demonstrate, among various protein clips, the existence of the intact free (unPEGylated) FBSP-V/I ADNECTIN™ in the des Met form with oxidation (+32). The dimeric form of the same species can also be seen. - For a sample with the following sequence (SEQ ID NO: 9):
-
MGVSDVPRDL EVVAATPTSL LISWSARLKV ARYYRITYGE TGGNSPVQEF TVPKNVYTAT ISGLKPGVDY TITVYAVTRF RDYQPISINY RTEI KPSTS TSTVS VPRD LEVVAATPTS LLISWRHPHF PTRYYRITYG ETGGNSPVQE FTVPLQPPTA TISGLKPGVD YTITVYAVT GRNGRLLSIP ISINYRTEI KPCQ
Several D residues are involved in fragmentation (in bold, italic font), with D95 and D200 (underlined) being the primary sites. With heat stress, cleavage also occurs at the maleimide bond of the PEG conjugation, resulting in the release of free FBSP-V/I (shown as “VI des Met”). -
FIG. 11 shows a comparison of dePEGylation of several ADNECTINS™, as a measure of free PEG over the course of 1-4 weeks. The exemplary ADNECTINS™ are FBSP-P (samples F1, F2, and F3) stored at pH 6.0; FBSP-V/I stored at pH 5.5; FBSP-V stored at pH 5.0; and FBSP-E/I stored at pH 4.0. FBSP-E/I is a multivalent polypeptide comprising two 10Fn3 domains with the BC, DE and FG loops altered such that one 10Fn3 domain binds with high affinity to EGFR and the other 10Fn3 domain binds with high affinity to IGF-IR. - A question arose as to the exact structure and functionality of the free PEG lost from the ADNECTINS™ during stability. Based on elution time by RP-HPLC, the free PEG peak appeared to closely resemble the unstressed PEG in terms of hydrophobicity, which would imply that the liberated free PEG remained largely intact and was close in molecular weight and size to the unstressed PEG.
- The preferred pH range for conjugation through maleimide chemistry is 6.5 to 7.5, and in the past the PEGylation step for ADNECTINS™ has been conducted at
pH 5 to 5.5 using the PEG in solid form. To address functionality, PEG solutions were prepared using MILLI-Q® water (pH˜5.5) and 50 mM Tris (pH 7.0). The solutions were stressed at 37° C. for one week, and their functionality was assessed through a PEGylation reaction with the FBSP-Vfree ADNECTIN™. ThepH 7 solution was pH adjusted to ˜5.5 prior to the reaction for a more direct comparison to the PEG in water. The data in Table 4 shows that, after stress, some of the maleimide functional group on the PEG was lost in the pH 5.5 solution and that the functionality was completely lost in the pH 7.0 solution. -
-
TABLE 1 Summary of MS results on the protein fragments shown in FIG. 3. The molecular weight of FBSP-P cannot be determined due to the heterogeneity associated with the PEGylation. % Difference Peak from Retention Observed Theoretical Theoretical Time (min) MW (Da) MW (Da) MW Structure 5.7 11337.3 11338.72 −0.01 Des Met form of FBSP-Pfree (G2-A104) 6.0 22670.1 22675.44 −0.02 Des Met form of FBSP-Pfree dimer (disulfide linked) -
TABLE 2 Summary of MS results on the protein fragments shown in FIG. 8. Peak % Difference Retention from Time Observed Theoretical Theoretical (min) MW (Da) MW (Da) MW Structure 4.6 6866 6868.7 −0.04 I28-D91 5.3 10361 10362.7 −0.02 FBSP-Vfree ADNECTIN ™ (des Met form) 5.5 20723 20723.4 0.00 FBSP-Vfree ADNECTIN ™ dimer (des Met form) 5.7 9888 9888.2 0.00 (G2 to D91)-water (DK cleavage product) -
TABLE 3 Relative quantification of protein fragments in FBSP-V stressed samples. Quantification is based on total UV area at 280 nm including the FBSP-V product peak. “Total pre-peaks” refers to all pre-peaks detected before the elution of FBSP-V product including all clips and intact FBSP-Vfree species; “free FBSP-Vfree ADNECTIN ™” refers to the sum of free (unPEGylated) FBSP-Vfree ADNECTIN ™ and FBSP-Vfree dimer. Total % Pre-peaks % Free (Clips + FBSP-Vfree Mol % FBSP-Vfree ADNECTIN ™ Free FBSP-V Formulation ADNECTIN ™) Only PEG 10 mM Sodium Acetate, 7.0% 0.0% 0.63 5% mannitol, pH 4.5; 5 mg/ mL 10 mM Sodium Acetate, 2.9% 1.7% 1.01 5% mannitol, pH 5.5; 5 mg/ mL 10 mM Sodium Acetate, 2.7% 1.9% 1.60 5% mannitol, pH 6.5; 5 mg/ mL 10 mM Sodium Acetate, 3.3% 2.4% 1.56 5% mannitol, pH 6.5; 10 mg/mL -
TABLE 4 Conjugation efficiency of 40k PEG maleimide after heat and pH stresses % Unconjugated FBSP-Vfree ADNECTIN ™ PEG in MQ water PEG in 50 mM Tris Stress Conditions (pH ~5.5) (pH 7.0) T = 0 15.9% 15.9% T = 1 week, 37 C. 33.1% 100% - FBSP-P. Two lots of FBSP-P (
lots 1 and 2) were used in two separate pH studies covering the range ofpH 4 to 7.5, at half pH unit intervals. The samples were formulated using the high throughput formulation format on a TECAN® robot. The drug substance (10 mg/mL, in 10 mM succinate, pH 6.0) was mixed with concentrates of succinate buffers (frompH 4 to 7.5) and sorbitol, which resulted in a final protein concentration of 1 mg/mL or 10 mg/mL in the excipients and pH described in the results section. The samples were put on stability in 96-well plate format and tested directly out of the plates. - FBSP-V/I. The FBSP-V/I sample was formulated using tangential flow filtration (TFF), filled in vials and subject to stability testing as described herein.
- FBSP-V. The samples were formulated by TFF into the buffers indicated, filled in vials and subject to stability testing as described herein.
- RP-UV-ELSD. A PLRP-S column (4.6*150 mm, Polymer Labs) was used for the analysis of FBSP-P samples. The protein fragments were analyzed on a relative percent basis at 280 nm using UV detection, and the free PEG moiety was quantified on a mole % basis using a 5-point PEG calibration curve with evaporative light scattering (ELS) detection. The method utilizes a water/acetonitrile/trifluoroacetic acid gradient.
- RP-UV. A Jupiter C18 column (4.6*250 mm, PHENOMENEX®) was used for the analysis of FBSP-V and FBSP-V/I samples. The protein fragments were analyzed on a relative percent basis at 280 nm using UV detection. The method utilizes a water/acetonitrile/trifluoroacetic acid gradient.
- LC-MS. The HPLC method using the Jupiter C18 column was coupled to a Thermo LTQ ion trap mass spectrometer, and the flow was split after the UV detector with 0.2 mL/min introduced into the ionization source of the MS. The MS data obtained was deconvoluted using the MagTran software, and structures were assigned to the detected masses using the PAWS software.
- For expression of FBSP, a nucleotide sequence encoding the construct is cloned into an inducible expression vector and is expressed in E. coli cells (either as a soluble fraction or into intracellular inclusion bodies). Cell bank vials generated from a culture of a single plated colony are used to inoculate a shake flask culture as an inoculum for a large-scale fermentor. Alternatively, a seed fermentor is used for an inoculum culture, depending on the final fermentation volume. The large-scale fermentation contains a growth phase to accumulate biomass and a production phase to generate the FBSP.
- For insoluble FBSP, intracellular inclusion bodies are released from harvested cells using a MICROFLUIDIZER® and recovered by centrifugation, followed by washes with buffer and water. The purification process for insoluble FBSP uses a Guanidine-HCl based resolubilization of inclusion bodies, followed by refolding the protein.
- For soluble FBSP, cells were pelleted and lysed using a MICROFLUIDIZER® and the soluble fraction was recovered by centrifugation, and the supernatant was clarified by filtration.
- The protein is then purified using one or more columns, such as a HISTRAP® column, a cation exchange chromatography column, and/or a hydrophobic interaction column. The resulting purified FBSP is then covalently linked to a PEG via maleimide chemistry at a single cysteine residue to produce PEGylated protein.
- The PEGylated protein may then be purified over one or more additional columns, such as a cation exchange chromatography column. The elution is concentrated to a target protein concentration and then exchanged into the formulation buffer using ultrafiltration/diafiltration (UF/DF). The UF/DF product is filtered using a final 0.22 μm filter. The filtered product is then filled into vials to produce the final product.
- This Example shows that dePEGylation at neutral or alkaline pH occurs not only with polypeptides and proteins, but also with smaller peptides. This Example also shows that dePEGylation occurs regardless of the type of linker connecting the PEG moiety to the peptide and regardless of the type of PEG.
- A synthetic peptide, TEIEKPCQ (SEQ ID NO: 47), bearing the same C-terminal sequence as wildtype 10FN3 proteins, was utilized as a model peptide for conjugation to three different 40 kD PEG-MALs at its penultimate cysteine residue. The structures of the three PEG-MALs are described below:
- 2-Branched PEG-MAL, with a C2 alkyl linker (NOF p/n Sunbright GL2-400MA;
FIG. 12 ) - 2-Branched PEG-MAL, with a C5 alkyl linker (NOF p/n Sunbright GL2-400MA3)
- Linear PEG-MAL, with a C2 alkyl linker (NOF p/n Sunbright ME-400MA)
- The PEG conjugated peptides were purified using PD-10 columns and formulated into 1x PBS at pH 8.3. The formulated peptides were analyzed at T=0 and then at 1 week after heat stress at 37° C. for level of dePEGylation.
- The samples were analyzed for dePEGylation by RP-HPLC. A Polaris C8-A column (2.1*150 mm, VARIAN®) was used for the analysis of PEGylated peptide samples. The free peptide was quantified on a relative percent basis to the intact sample at 214 nm using UV detection. The method utilizes a water/acetonitrile/trifluoroacetic acid gradient. For peak identification, LC-MS was conducted.
- The results, which are shown in
FIGS. 13 , 14 and 15, indicate that a higher level of dimerized free peptide was observed in each of the 3 stressed samples relative to the level in each of the samples at T=0. The bar graph inFIG. 15 demonstrates an increase in the relative level of the free peptide, in the form of a covalent dimer, for all three conjugated peptides after heat stress. The free peptide generated formed a covalent dimer due to the free cysteine now available as a result of dePEGylation, which was confirmed by MS and MS/MS analysis. The fact that the level of the covalent dimer increased after heat stress further indicates that the dePEGylation event regenerated an intact free peptide containing a free cysteine residue. A low level of the free peptide was present at T0 for all three samples due to its incomplete removal with the PD-10 column purification. However, a measurable increase in the level of the free peptide was still observed. - Thus, the results indicate that dePEGylation can also occur with a short peptide (i.e., not only with a larger polypeptide or protein). Moreover, the results show that dePEGylation is not greatly affected by the length of the alkyl linker, nor by the branching structure in the PEG-MAL, as all three samples underwent dePEGylation to a similar extent.
- This Example shows that less dePEGylation of a small PEGylated peptide occurs at lower pH relative to higher pH.
- A synthetic peptide consisting of the amino acid sequence TEIDKPCQ (SEQ ID NO: 48) was conjugated to a 2kPEG-MAL. Briefly, the peptide was solubilized in NaOAc at pH 5.5. PEG in water was added to the peptide and the conjugation reaction occurred overnight. The sample was cleaned up via buffer exchange over PD-10 columns into pH 8.0 Tris or pH 5.5 NaOAc. The two samples were stressed at 37° C. for one week, followed by analysis using RP-HPLC, as described in Example 5.
- The results, which are shown in
FIG. 16 , indicate that, similarly to larger polypeptides, smaller peptides are subject to less dePEGylation at lower pH, compared to higher pH. - This Example shows that reducing the pH reduces dePEGylation of proteins regardless of whether they contain a large PEG, a small PEG, a branched PEG or a linear PEG.
- C7 protein (SEQ ID NO: 48), was conjugated to a variety of PEG-MALs with different molecular weights, including 2 k, 5 k, 10 k, 12 k, 20 k, 20 k bis (bi-functional), 30 k and 40 k branched (NOF America Corp.). Each sample was purified over an ion-exchange column, then formulated in 50 mM sodium acetate at pH 4.5 or 50 mM Tris at pH 8.0. The samples were heat stressed at 37° C. for one week and the results were measured by RP-HPLC using a Jupiter C18 column (4.6*250 mm, PHENOMENEX®). The protein fragments were quantified on a relative percent basis to the intact sample at 280 nm using UV detection. The method utilizes a water/acetonitrile/trifluoroacetic acid gradient. For peak identification, LC-MS was conducted.
- The results, which are shown in
FIG. 17 , indicate a substantially higher level of dePEGylation after the heat stress in the samples at pH 8.0 relative to the samples at pH 5.5. In addition, the results also indicate no difference in the level of degradation among the different sizes of PEG-MALs used in the conjugation. - The entire disclosure of each document cited (including patents, patent applications, journal articles, abstracts, laboratory manuals, books, GENBANK® Accession numbers, SWISS-PROT® Accession numbers, or other disclosures) in the Background, Detailed Description, Brief Description of the Drawings, and Examples is hereby incorporated herein by reference in their entirety.
- The present invention is not to be limited in scope by the embodiments disclosed herein, which are intended as single illustrations of individual aspects of the invention, and any that are functionally equivalent are within the scope of the invention. Various modifications to the models and methods of the invention, in addition to those described herein, will become apparent to those skilled in the art from the foregoing description and teachings, and are similarly intended to fall within the scope of the invention. Such modifications or other embodiments can be practiced without departing from the true scope and spirit of the invention.
-
SEQUENCES Naturally occurring human 10Fn3 (SEQ ID NO: 1) VSDVPRDLEVVAATPTSLLISWDAPAVTVRYYRITYGETGGNSPVQEFTVPGSKS T ATISGLKPGVDYTITVYAVTGRGDSPASSKPISINYRT Full length wild-type human 10Fn3 domain (SEQ ID NO: 47) VSDVPRDLEVVAATPTSLLISWDAPAVTVRYYRITYGETGGNSPVQEFTVPGSKS T ATISGLKPGVDYTITVYAVTGRGDSPASSKPISINYRTEIDKPSQ Antibody-like protein based on the 10Fn3 scaffold (SEQ ID NO: 2) EVVAAT(X)a SLLI(X)x YYRITYGE(X)b QEFTV(X)y ATI(X)c DYTITVYAV(X)zISINYR T Antibody-like protein based on the 10Fn3 scaffold (SEQ ID NO: 3) EVVAATPTSLLI(X)x YYRITYGETGGNSPVQEFTV(X)y ATISGLKPGVDYTITVYAV (X)z ISINYRT V core (SEQ ID NO: 4) EVVAATPTSLLISWRHPHFPTRYYRITYGETGGNSPVQEFTVPLQPPTATISGLKPG VDYTITVYAVTDGRNGRLLSIPISINYRT Full length FBSP-V (SEQ ID NO: 48) GEVVAATPTSLLISWRHPHFPTRYYRITYGETGGNSPVQEFTVPLQPPTATISGLKP GVDYTITVYAVTDGRNGRLLSIPISINYRTEIDKPCQ Short Tail (SEQ ID NO: 5) EIEK VEGFR2 BC Loop (SEQ ID NO: 6) RHPHFPT VEGFR2 DE Loop (SEQ ID NO: 7) LQPP VEGFR2 FG Loop (SEQ ID NO: 8) DGRNGRLLSI DK + VEGFR2/IGF-IR Binder (SEQ ID NO: 9) MGVSDVPRDLEVVAATPTSLLISWSARLKVARYYRITYGETGGNSPVQEFTVPKN VYTATISGLKPGVDYTITVYAVTRFRDYQPISINYRTEIDKPSTSTSTVSDVPRDLE VVAATPTSLLISWRHPHFPTRYYRITYGETGGNSPVQEFTVPLQPPTATISGLKPG VDYTITVYAVTDGRNGRLLSIPISINYRTEIDKPCQ Modified Cys Tail (SEQ ID NO: 10) EGSGC Cys Tail (SEQ ID NO: 11) EIEKPCQ EIEKPC (SEQ ID NO: 12) (SEQ ID NO: 13) VSDVPRDLEVVAATPTSLLISWDAPAVTVRYYRITYGETGGNSPVQEFTVPGSKS TATISGLKPGVDYTITVYAVTGRGDSPASSKPISINYRT Extension sequence (SEQ ID NO: 14) EIDKPSQ I core (SEQ ID NO: 15) EVVAATPTSLLISWSARLKVARYYRITYGETGGNSPVQEFTVPKNVYTATISGLKP GVDYTITVYAVTRFRDYQPISINYRT Extension sequence (SEQ ID NO: 16) EIDKPSQLE MGVSDVPRDL (SEQ ID NO: 17) VSDVPRDL (SEQ ID NO: 18) GVSDVPRDL (SEQ ID NO: 19) XnSDVPRDL, wherein n = 0, 1 or 2 amino acids, wherein when n = 1, X is Met or Gly, and when n = 2, X is Met-Gly (SEQ ID NO: 20) XnDVPRDL, wherein n = 0, 1 or 2 amino acids, wherein when n = 1, X is Met or Gly, and when n = 2, X is Met-Gly (SEQ ID NO: 21) XnVPRDL, wherein n = 0, 1 or 2 amino acids, wherein when n = 1, X is Met or Gly, and when n = 2, X is Met-Gly (SEQ ID NO: 22) XnPRDL, wherein n = 0, 1 or 2 amino acids, wherein when n = 1, X is Met or Gly, and when n = 2, X is Met-Gly (SEQ ID NO: 23) XnRDL, wherein n = 0, 1 or 2 amino acids, wherein when n = 1, X is Met or Gly, and when n = 2, X is Met-Gly (SEQ ID NO: 24) XnDL, wherein n = 0, 1 or 2 amino acids, wherein when n = 1, X is Met or Gly, and when n = 2, X is Met-Gly (SEQ ID NO: 25) EIEKPSQ (SEQ ID NO: 26) EIEKP (SEQ ID NO: 27) EIEKPS (SEQ ID NO: 28) EIDK (SEQ ID NO: 29) EIDKPCQ (SEQ ID NO: 30) Fn linker (SEQ ID NO: 31) PSTSTST GS5 linker (SEQ ID NO: 32) GSGSGSGSGS GS10 linker (SEQ ID NO: 33) GSGSGSGSGSGSGSGSGSGS (GGGGS)3 (SEQ ID NO: 34) GGGGS GGGGS GGGGS (GGGGS)5 (SEQ ID NO: 35) GGGGS GGGGS GGGGS GGGGS GGGGS G4SG4SG3SG (SEQ ID NO: 36) GGGGSGGGGSGGGSG GPG (SEQ ID NO: 37) GPGPGPG (SEQ ID NO: 38) GPGPGPGPGPG (SEQ ID NO: 39) PA3 linker (SEQ ID NO: 40) PAPAPA PA6 linker (SEQ ID NO: 41) PAPAPAPAPAPA PA9 linker (SEQ ID NO: 42) PAPAPAPAPAPAPAPAPA E Core (SEQ ID NO: 43) EVVAATPTSLLISWWAPVDRYQYYRITYGETGGNSPVQEFTVPRDVYTATISGLK PGVDYTITVYAVTDYKPHADGPHTYHESPISINYRT IGF-IR BC Loop (SEQ ID NO: 44) SARLKVA IGF-IR DE Loop (SEQ ID NO: 45) KNVY IGF-IR FG Loop (SEQ ID NO: 46) RFRDYQ TEIEKPCQ (SEQ ID NO: 47) TEIDKPCQ (SEQ ID NO: 48)
Claims (26)
1. A composition comprising a polypeptide conjugated to a PEG moiety through a maleimide linker, wherein the composition has a pH between pH 2.0 and pH 6.0.
2-3. (canceled)
4. The composition of claim 2, wherein less than 5% of the maleimide linkers are cleaved over a four week storage period.
5. The composition of claim 4 , wherein the polypeptide comprises a tenth fibronectin type III (10Fn3) domain having an altered amino acid sequence relative to the wild-type sequence that binds to a target molecule with a KD of less than 500 nM.
6. (canceled)
7. The composition of claim 6 , wherein the 10Fn3 domain does not contain a DK sequence in the C-terminal tail region.
8. The composition of claim 7 , wherein the C-terminal tail of the 10Fn3 domain comprises a cysteine residue, to which the PEG moiety is linked.
9-13. (canceled)
14. The composition of claim 8 , wherein the maleimide linker forms a thioether bond with a sulfhydryl group on the polypeptide.
15-17. (canceled)
18. A method for maintaining PEGylation of polypeptides during storage, comprising storing the polypeptides in a solution buffered to a pH between pH 2.0 and pH 6.0, wherein the polypeptides are conjugated to a polyethylene glycol (PEG) moiety through a maleimide linker, and wherein less than 5% of the maleimide linkers are cleaved over a four week storage period.
19. The method of claim 18 , wherein less than 5% of the maleimide linkers are cleaved over an eight week storage period.
20-22. (canceled)
23. The method of claim 18 , wherein the polypeptides comprise a tenth fibronectin type III (10Fn3) domain having an altered amino acid sequence relative to the wild-type sequence that binds to a target molecule with a KD of less than 500 nM.
24. The method of claim 23 , wherein the 10Fn3 domain does not contain a DK sequence in the C-terminal tail region.
25. The method of claim 24 , wherein the C-terminal tail of the 10Fn3 domain comprises a cysteine residue.
26-29. (canceled)
30. The method of claim 18 , wherein the maleimide linker forms a thioether bond with a sulfhydryl group on the polypeptides.
31. The method of claim 24 , wherein the pH of the solution is between 3.0 and 4.0.
32. The method of claim 24 , wherein the pH of the solution is between 3.5 and 4.5.
33. The method of claim 24 , wherein the pH of the solution is between 4.0 and 5.0.
34. The method of claim 24 , wherein the pH of the solution is between 4.5 and 5.5.
35. The method of claim 24 , wherein the pH of the solution is between 5.0 and 6.0.
36. The method of claim 24 , wherein the concentration of the PEGylated polypeptides in the solution is from 1-10 mg/mL.
37. The method of claim 24 , wherein the PEGylated polypeptides are stored at a temperature from 4° C. to 30° C.
38. A method for improving the stability of PEGylated polypeptides in a solution, wherein the polypeptides are conjugated to a polyethylene glycol (PEG) moiety through a maleimide linker, comprising the steps of:
(a) determining the amount of PEG cleaved from the polypeptides over a fixed storage period in the solution; and
(b) if PEG is cleaved from more than 5% of the polypeptides over the storage period, reformulating the PEGylated polypeptides in a storage solution buffered to a pH of between 2.0-6.0.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/117,458 US20140187488A1 (en) | 2011-05-17 | 2012-05-15 | Methods for maintaining pegylation of polypeptides |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161487027P | 2011-05-17 | 2011-05-17 | |
US14/117,458 US20140187488A1 (en) | 2011-05-17 | 2012-05-15 | Methods for maintaining pegylation of polypeptides |
PCT/US2012/037908 WO2012158678A1 (en) | 2011-05-17 | 2012-05-15 | Methods for maintaining pegylation of polypeptides |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2012/037908 A-371-Of-International WO2012158678A1 (en) | 2011-05-17 | 2012-05-15 | Methods for maintaining pegylation of polypeptides |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/253,358 Continuation US10898538B2 (en) | 2011-05-17 | 2016-08-31 | Methods for maintaining pegylation of polypeptides |
Publications (1)
Publication Number | Publication Date |
---|---|
US20140187488A1 true US20140187488A1 (en) | 2014-07-03 |
Family
ID=46208778
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/117,458 Abandoned US20140187488A1 (en) | 2011-05-17 | 2012-05-15 | Methods for maintaining pegylation of polypeptides |
US15/253,358 Active 2033-02-09 US10898538B2 (en) | 2011-05-17 | 2016-08-31 | Methods for maintaining pegylation of polypeptides |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/253,358 Active 2033-02-09 US10898538B2 (en) | 2011-05-17 | 2016-08-31 | Methods for maintaining pegylation of polypeptides |
Country Status (3)
Country | Link |
---|---|
US (2) | US20140187488A1 (en) |
EP (1) | EP2709669A1 (en) |
WO (1) | WO2012158678A1 (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1711196A4 (en) | 2003-12-05 | 2011-09-14 | Bristol Myers Squibb Co | Inhibitors of type 2 vascular endothelial growth factor receptors |
EP2727936B1 (en) | 2006-11-22 | 2016-09-07 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR |
EP2247615B1 (en) | 2008-02-14 | 2014-07-30 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins that bind egfr |
AR071874A1 (en) | 2008-05-22 | 2010-07-21 | Bristol Myers Squibb Co | ARMAZON DOMAIN PROTEINS BASED ON MULTIVALENT FIBRONECTINE |
TWI496582B (en) | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | Bispecific egfr/igfir binding molecules |
TW201138808A (en) | 2010-05-03 | 2011-11-16 | Bristol Myers Squibb Co | Serum albumin binding molecules |
US9562089B2 (en) | 2010-05-26 | 2017-02-07 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins having improved stability |
ES2608835T3 (en) | 2011-04-13 | 2017-04-17 | Bristol-Myers Squibb Company | Fc fusion proteins comprising new linkers or arrangements |
US20140187488A1 (en) | 2011-05-17 | 2014-07-03 | Bristol-Myers Squibb Company | Methods for maintaining pegylation of polypeptides |
JP2015504038A (en) | 2011-10-31 | 2015-02-05 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Fibronectin binding domain with reduced immunogenicity |
MY172863A (en) | 2012-09-13 | 2019-12-13 | Bristol Myers Squibb Co | Fibronectin based scaffold domain proteins that bind to myostatin |
WO2014120891A2 (en) | 2013-02-01 | 2014-08-07 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins |
US10787498B2 (en) | 2013-02-06 | 2020-09-29 | Bristol-Myers Squibb Company | Fibronectin type III domain proteins with enhanced solubility |
US10065987B2 (en) | 2013-02-12 | 2018-09-04 | Bristol-Myers Squibb Company | High pH protein refolding methods |
CN113150117A (en) | 2014-03-20 | 2021-07-23 | 百时美施贵宝公司 | Novel serum albumin binding fibronectin type III domain |
EP3708580B1 (en) | 2015-09-23 | 2023-11-01 | Bristol-Myers Squibb Company | Fast-off rate serum albumin binding fibronectin type iii domains |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070009478A1 (en) * | 2005-06-01 | 2007-01-11 | Maxygen Holdings Ltd. | Pegylated g-csf polypeptides and methods of producing same |
Family Cites Families (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4002531A (en) | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
US5641648A (en) | 1986-11-04 | 1997-06-24 | Protein Polymer Technologies, Inc. | Methods for preparing synthetic repetitive DNA |
US6018030A (en) | 1986-11-04 | 2000-01-25 | Protein Polymer Technologies, Inc. | Peptides comprising repetitive units of amino acids and DNA sequences encoding the same |
US5514581A (en) | 1986-11-04 | 1996-05-07 | Protein Polymer Technologies, Inc. | Functional recombinantly prepared synthetic protein polymer |
US5770697A (en) | 1986-11-04 | 1998-06-23 | Protein Polymer Technologies, Inc. | Peptides comprising repetitive units of amino acids and DNA sequences encoding the same |
US5766897A (en) | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
JP3051145B2 (en) | 1990-08-28 | 2000-06-12 | 住友製薬株式会社 | Novel polyethylene glycol derivative modified peptide |
US5792742A (en) | 1991-06-14 | 1998-08-11 | New York University | Fibrin-binding peptide fragments of fibronectin |
US5281698A (en) | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
ATE225801T1 (en) | 1992-07-13 | 2002-10-15 | Bionebraska Inc | METHOD FOR MODIFYING RECOMBINANT POLYPEPTIDES |
US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
WO1994017097A1 (en) | 1993-01-19 | 1994-08-04 | Regents Of The University Of Minnesota | Synthetic fibronectin fragments as inhibitors of retroviral infections |
US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
ATE332368T1 (en) | 1997-01-21 | 2006-07-15 | Gen Hospital Corp | SELECTION OF PROTEINS USING RNA-PROTEIN FUSIONS |
US6261804B1 (en) | 1997-01-21 | 2001-07-17 | The General Hospital Corporation | Selection of proteins using RNA-protein fusions |
ES2301198T3 (en) | 1997-06-12 | 2008-06-16 | Novartis International Pharmaceutical Ltd. | ARTIFICIAL POLYPEPTIDES OF ANTIBODIES. |
ATE340870T1 (en) | 1998-04-03 | 2006-10-15 | Compound Therapeutics Inc | ADDRESSABLE PROTEIN ARRAYS |
JP4562286B2 (en) | 1998-12-10 | 2010-10-13 | ブリストル−マイヤーズ スクウィブ カンパニー | Protein mimetics of antibody mimics and other binding proteins |
GB9827228D0 (en) | 1998-12-10 | 1999-02-03 | Univ Nottingham | Cancer detection method and reagents |
US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
CA2404528A1 (en) | 2000-03-31 | 2001-10-04 | Institut Pasteur | Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof |
ES2564161T3 (en) | 2000-07-11 | 2016-03-18 | Research Corporation Technologies, Inc | Artificial antibody polypeptides |
ES2367891T3 (en) | 2000-09-29 | 2011-11-10 | Schering Corporation | INTERLEUCINA-10 PEGILADA. |
CA2418835A1 (en) | 2000-10-16 | 2002-04-25 | Phylos, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US7598352B2 (en) | 2000-11-17 | 2009-10-06 | University Of Rochester | Method of identifying polypeptide monobodies which bind to target proteins and use thereof |
AU2002307146B2 (en) | 2001-04-04 | 2007-02-01 | University Of Rochester | AlphaNuBeta3 integrin-binding polypeptide monobodies and their use |
US20100081792A1 (en) | 2001-06-28 | 2010-04-01 | Smithkline Beecham Corporation | Ligand |
WO2003104418A2 (en) | 2002-06-06 | 2003-12-18 | Research Corporation Technologies, Inc. | Reconstituted polypeptides |
AU2003265361A1 (en) * | 2002-08-28 | 2004-03-19 | Pharmacia Corporation | Stable ph optimized formulation of a modified antibody |
US20080220049A1 (en) | 2003-12-05 | 2008-09-11 | Adnexus, A Bristol-Myers Squibb R&D Company | Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins |
EP1711196A4 (en) | 2003-12-05 | 2011-09-14 | Bristol Myers Squibb Co | Inhibitors of type 2 vascular endothelial growth factor receptors |
WO2006041942A2 (en) | 2004-10-04 | 2006-04-20 | Qlt Usa, Inc. | Ocular delivery of polymeric delivery formulations |
KR100735784B1 (en) * | 2005-07-20 | 2007-07-06 | 재단법인 목암생명공학연구소 | Mutant of granulocyte-colony stimulating factorG-CSF and chemically conjugated polypeptide thereof |
WO2008031098A1 (en) | 2006-09-09 | 2008-03-13 | The University Of Chicago | Binary amino acid libraries for fibronectin type iii polypeptide monobodies |
EP2727936B1 (en) | 2006-11-22 | 2016-09-07 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR |
US20100144599A1 (en) | 2007-02-02 | 2010-06-10 | Bristol-Myers Squibb Company | Vegf pathway blockade |
US20090176654A1 (en) | 2007-08-10 | 2009-07-09 | Protelix, Inc. | Universal fibronectin type III binding-domain libraries |
US8470966B2 (en) | 2007-08-10 | 2013-06-25 | Protelica, Inc. | Universal fibronectin type III binding-domain libraries |
US8680019B2 (en) | 2007-08-10 | 2014-03-25 | Protelica, Inc. | Universal fibronectin Type III binding-domain libraries |
EP2197476A2 (en) | 2007-08-20 | 2010-06-23 | Bristol-Myers Squibb Company | Use of vegfr-2 inhibitors for treating metastatic cancer |
WO2009058379A2 (en) | 2007-10-31 | 2009-05-07 | Medimmune, Llc | Protein scaffolds |
US20110034384A1 (en) | 2007-11-28 | 2011-02-10 | Bristol-Myers Squibb Company | COMBINATION VEGFR2 THERAPY WITH mTOR INHIBITORS |
AU2008345674A1 (en) | 2007-12-19 | 2009-07-09 | Centocor, Ortho Biotech Inc. | Alternative scaffold protein fusions phage display via fusion to pIX of M13 phage |
EA201000979A1 (en) | 2007-12-27 | 2011-02-28 | Новартис Аг | IMPROVED BINDING MOLECULES BASED ON FIBRONECTIN AND THEIR APPLICATION |
EP2247615B1 (en) | 2008-02-14 | 2014-07-30 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins that bind egfr |
US9296810B2 (en) | 2008-05-02 | 2016-03-29 | Novartis Ag | Fibronectin-based binding molecules and uses thereof |
AR071874A1 (en) | 2008-05-22 | 2010-07-21 | Bristol Myers Squibb Co | ARMAZON DOMAIN PROTEINS BASED ON MULTIVALENT FIBRONECTINE |
WO2010027326A1 (en) | 2008-09-03 | 2010-03-11 | Nanyang Technological University | Peptide nucleic acid monomers and oligomers |
US8415291B2 (en) | 2008-10-31 | 2013-04-09 | Centocor Ortho Biotech Inc. | Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses |
KR101781907B1 (en) | 2008-10-31 | 2017-09-26 | 얀센 바이오테크 인코포레이티드 | Fibronectin type iii domain based scaffold compositions, methods and uses |
TWI496582B (en) * | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | Bispecific egfr/igfir binding molecules |
EP2379718B2 (en) | 2008-12-16 | 2020-12-30 | Novartis AG | Yeast display systems |
EP2396000A1 (en) | 2009-02-11 | 2011-12-21 | Bristol-Myers Squibb Company | Combination vegfr2 therapy with temozolomide |
EP2396011B1 (en) | 2009-02-12 | 2016-04-13 | Janssen Biotech, Inc. | Fibronectin type iii domain based scaffold compositions, methods and uses |
US8067201B2 (en) * | 2009-04-17 | 2011-11-29 | Bristol-Myers Squibb Company | Methods for protein refolding |
WO2011020033A2 (en) | 2009-08-13 | 2011-02-17 | Massachusetts Institute Of Technology | Engineered proteins including mutant fibronectin domains |
EP3434769B1 (en) | 2009-10-30 | 2020-11-25 | Novartis AG | Universal fibronectin type iii bottom-side binding domain libraries |
WO2011051466A1 (en) | 2009-11-02 | 2011-05-05 | Novartis Ag | Anti-idiotypic fibronectin-based binding molecules and uses thereof |
US20110123545A1 (en) | 2009-11-24 | 2011-05-26 | Bristol-Myers Squibb Company | Combination of vegfr2 and igf1r inhibitors for the treatment of proliferative diseases |
WO2011092233A1 (en) | 2010-01-29 | 2011-08-04 | Novartis Ag | Yeast mating to produce high-affinity combinations of fibronectin-based binders |
CA2788972A1 (en) | 2010-02-12 | 2011-08-18 | University Of Rochester | Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies |
EA201270713A1 (en) | 2010-02-18 | 2013-01-30 | Бристол-Майерс Сквибб Компани | PROTEINS BASED ON FIBRONECTIN WITH FRAMED DOMAINS THAT BIND IL-23 |
EP3424949A1 (en) | 2010-04-13 | 2019-01-09 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind pcsk9 |
CA2795325A1 (en) | 2010-04-13 | 2011-10-20 | Medimmune, Llc | Fibronectin type iii domain-based multimeric scaffolds |
KR101863033B1 (en) | 2010-04-30 | 2018-06-01 | 얀센 바이오테크 인코포레이티드 | Stabilized fibronectin domain compositions, methods and uses |
TW201138808A (en) | 2010-05-03 | 2011-11-16 | Bristol Myers Squibb Co | Serum albumin binding molecules |
US9562089B2 (en) | 2010-05-26 | 2017-02-07 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins having improved stability |
EP3222631A3 (en) | 2010-07-30 | 2017-11-22 | Novartis AG | Fibronectin cradle molecules and libraries thereof |
CN103380143B (en) | 2010-12-22 | 2016-01-06 | 百时美施贵宝公司 | In conjunction with the scaffold domains protein based on fibronectin of IL-23 |
WO2012094653A2 (en) | 2011-01-07 | 2012-07-12 | Massachusetts Institute Of Technology | Compositions and methods for macromolecular drug delivery |
ES2608835T3 (en) | 2011-04-13 | 2017-04-17 | Bristol-Myers Squibb Company | Fc fusion proteins comprising new linkers or arrangements |
US8846042B2 (en) | 2011-05-16 | 2014-09-30 | Fabion Pharmaceuticals, Inc. | Multi-specific FAB fusion proteins and methods of use |
US20140187488A1 (en) | 2011-05-17 | 2014-07-03 | Bristol-Myers Squibb Company | Methods for maintaining pegylation of polypeptides |
EP2710382B1 (en) | 2011-05-17 | 2017-10-18 | Bristol-Myers Squibb Company | Improved methods for the selection of binding proteins |
WO2012162426A1 (en) | 2011-05-23 | 2012-11-29 | The University Of North Carolina At Chapel Hill | Methods and compositions for heptameric targeting ligands |
WO2012162418A1 (en) | 2011-05-23 | 2012-11-29 | The University Of North Carolina At Chapel Hill | Methods and compositions for heterodimeric targeting ligands |
EP4151785A1 (en) | 2011-09-27 | 2023-03-22 | Janssen Biotech, Inc. | Fibronectin type iii repeat based protein scaffolds with alternative binding surfaces |
-
2012
- 2012-05-15 US US14/117,458 patent/US20140187488A1/en not_active Abandoned
- 2012-05-15 EP EP12725925.7A patent/EP2709669A1/en not_active Withdrawn
- 2012-05-15 WO PCT/US2012/037908 patent/WO2012158678A1/en active Application Filing
-
2016
- 2016-08-31 US US15/253,358 patent/US10898538B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070009478A1 (en) * | 2005-06-01 | 2007-01-11 | Maxygen Holdings Ltd. | Pegylated g-csf polypeptides and methods of producing same |
Also Published As
Publication number | Publication date |
---|---|
US10898538B2 (en) | 2021-01-26 |
EP2709669A1 (en) | 2014-03-26 |
US20170049905A1 (en) | 2017-02-23 |
WO2012158678A1 (en) | 2012-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10898538B2 (en) | Methods for maintaining pegylation of polypeptides | |
US11161893B2 (en) | Fibronectin based scaffold proteins having improved stability | |
US11408093B2 (en) | Fibronectin binding domains with reduced immunogenicity | |
US11447538B2 (en) | Fibronectin based scaffold proteins | |
CN105175532B (en) | Fibronectin based scaffold domain proteins that bind PCSK9 | |
KR20160138133A (en) | Stabilized fibronectin based scaffold molecules | |
ES2500048T3 (en) | Procedure to purify pegylated erythropoietin | |
EP3286212B1 (en) | Polypeptides targeting hiv fusion | |
KR101711472B1 (en) | Functionalized polypeptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |